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Human saliva has received substantially less attention as a biofluid for the identification of 
novel biomarkers for diseases, albeit it reflects most of the compounds found in blood.  
Similarly, there are few studies on the lung microbiome or metabolome especially assessed 
through saliva as a biosample. In this clinical research study, it was established that certain 
metabolites and bacteria in saliva change in particular respiratory diseases, such as chronic 
obstructive pulmonary disease (COPD) and lung cancer, allowing differentiation from healthy 
patients.  
The metabolomic fingerprints of saliva were derived from Flow Infusion Electrospray Mass 
Spectrometry. ANOVA of the derived data followed by Principal Component Analysis 
suggested that fingerprints could differentiate between several respiratory diseases (COPD, 
lung cancer, asthma, pneumonia, idiopathic pulmonary fibrosis, bronchiectasis, and 
sarcoidosis) and “healthy” controls. Some individual metabolites were tentatively identified 
based on accurate mass predictions but more work is required to confirm these. 
The microbiomes were assessed by 16S rRNA amplicon sequencing. Analysis at genus level 
identified 11 genera, which significantly differed between the experimental classes. 
Assessment of the core microbiome has shown that Streptococcus was prevalent in every saliva 
sample. The COPD Exacerbation class was associated with a loss in a range of bacterial genera 
as shown by estimates of a-diversity. However, these samples displayed an increase in 
Staphylococcus. Other genera were reduced in abundance and this was shown by saliva from 
patients which were undergoing an exacerbation, had significantly lower bacterial loads when 
compared to the other categories. This in turn may offer insights with regards to the clinical 
features of respiratory diseases in relation to the levels of bacterial load during stable conditions 
or exacerbations.  
The metabolomic and microbiomic approaches presented here, both show similar variations 
with respect to the classification of the pulmonary conditions and controls, which makes human 
saliva a reliable, cost-effective, non-invasive biofluid with prospective uses in novel methods 
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CHAPTER 1 | Causes and Impact of Pulmonary Diseases in the United Kingdom 
 
1.1. | Statistical Overview on Pulmonary Diseases 
Pulmonary diseases kill one in five people in the United Kingdom (UK) and cause the NHS 
great expense, with over £6 billion a year, according to the Burden of Lung Disease Report 
(2006). Moreover, pulmonary diseases still cause more deaths than ischemic heart disease 
(IHD) in the UK and lung cancer (LC) continues to be the most prevalent cancer killer, 
exceeding those linked to breast cancer. On average, death rates from pulmonary diseases in 
the UK exceed those in the EU. The Burden of Lung Disease report (2006), indicates that 
respiratory diseases cost the NHS £6.6 billion, out of which £3 billion are expenses for the care 
system, £1.9 billion for the mortality costs and £1.7 billion for the illness costs.  
The major pulmonary diseases in the UK comprise pneumonia, asthma, cystic fibrosis, 
occupational lung disease (e.g. asbestosis), chronic obstructive pulmonary disease (COPD - an 
umbrella term covering chronic bronchitis and emphysema), obstructive sleep apnoea (OSA), 
scarring lung diseases and LC. Surveys of the general population conducted in 2012, on people 
in the UK living with a lung disease suggest that approximatively 12.7 million people have a 
history of asthma, COPD or another longstanding respiratory illness (Lung Disease Report, 




One in five men and one in four women consulted a general practitioner (GP) for a respiratory 
complaint (Burden of Lung Disease, 2006). Additionally, estimates from general practice 
records show that 8 million people have been diagnosed with asthma, 1.2 million with COPD 
and more than 150,000 with interstitial lung diseases such as idiopathic pulmonary fibrosis 
(IPF) or sarcoidosis (Table 1.1).  
 
Table 1.1 | Estimates of people in the UK living with a lung disease 
Estimated numbers of people in the UK living with a lung disease based on general practice 
records (British Lung Foundation, 2012). People that have been diagnosed with a pulmonary 
disease in the UK over the period of 2008-2012 based on the gender incidence. Asthma 
diagnoses have indicated the highest incidence in both males and females, followed by COPD 
with an average of approximately 1,200,000, bronchiectasis and obstructive sleep apnoea 
(OSA) closely tied, sarcoidosis, lung cancer with 85,796 and idiopathic pulmonary fibrosis 




British Lung Foundation (2016) have further highlighted how lung diseases are one of the 
leading causes of death in the UK. Over the course of 2008 – 2012, pulmonary diseases were 
responsible for 20% of all deaths. In 2012, there were 114,225 deaths caused by lung diseases 
in comparison with 158,383 deaths from cardiovascular diseases (Table 1.2). Despite the fact 
that the number of deaths from cardiovascular diseases is greater than lung diseases, over the 
5-year period (2008 – 2012) the proportion of deaths caused by cardiovascular diseases has 
been decreasing. The predominant lung diseases in the UK in terms of the highest numbers of 
mortalities are lung cancer and COPD (Figure 1.1). Both conditions are very often associated 




death. During 2012, lung cancer was responsible for 6.2% of all UK deaths, COPD for 5.3% 
and pneumonia for 5.1%. 
Pneumonia, arises mainly from two highly contagious bacterial strains that register 25.3% 
deaths and pulmonary fibrosis, the lung scarring condition caused by exposure to 
environmental pollutants and certain medicines, 4.6%. Occupational lung diseases, e.g. 
mesothelioma which can arise from exposure to asbestos fibres, have increased to a percentage 
of 2.1% (British Thoracic Society, 2006; British Lung Foundation, 2016). 
 
 
Table 1.2 | Prevalence of death causes in the UK during 2008-2012 
UK deaths by cause in all age groups during 2008 – 2012 (British Lung Foundation, 2012). 
The rates of mortality in both men and women during the period of 2008-2012 of the most 
life-threatening diseases in the UK, indicating cardiovascular diseases with percentages 
ranging between 28-32%, lung diseases with 20% and other diseases with percentages of 





There is a strong link between age, gender, regional variation, social deprivation and inequality 
with lung disease (Burden of Lung Disease, 2006). Approximatively 44% of all respiratory 
disease deaths can be related to social class inequalities in comparison with 28% from IHD. 
For instance, men aged 20 – 64 labouring in unskilled manual occupations are predisposed 14 
times more to die from COPD, than men employed in professional positions. 
 
The burden of respiratory diseases affects individuals and their families, producing high costs 
to the health care system as well (Office of Disease Prevention and Health Promotion, 2014). 
The need of new technologies that promote respiratory health through better prevention, 
detection, treatment and even education have become a priority in the medical field and a 
subject undergoing intense study in the research area. 
 
 
Figure 1.1 | UK deaths from lung diseases (2008-2012) 
Lung cancer (LC) primes with 31%, followed by chronic obstructive pulmonary disease (COPD) 
26.1%, pneumonia with 25.3%, idiopathic pulmonary fibrosis (IPF) 4.6% and other occupational 






1.2 | Chronic Obstructive Pulmonary Disease (COPD)  
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease, typically 
characterised by gradual reduction of the airflow into the lungs caused by the inflammation of 
the air passages and damage to the lung tissue (Health and Safety Executive, 2016). COPD is 
a life-threatening heterogeneous disease, an umbrella term that comprises the well-known 
respiratory conditions, chronic bronchitis and emphysema.  
Chronic bronchitis affects the airways (bronchi) and emphysema affects the air sacs (alveoli) 
in the lungs as shown below in Figure 1.2 (British Lung Foundation, 2012). 
 
 
Figure 1.2 | Pathology of the lung affected by emphysema or chronic bronchitis 
Emphysema and chronic bronchitis are subdivisions of the respiratory condition COPD, 
affecting the bronchi and the alveoli in the lungs (Houghton, 2013). 
 
1.2.1 | Statistics in COPD  
COPD is common in later life, it becomes apparent after 40 or 50 years of age (Halbert et al., 
2006; WHO, 2016). Over the period of 2008-2012, around a million individuals in the UK have 




year (Health and Safety Executive, 2016). Global estimates (WHO, 2015) show that 
approximatively 3 million deaths were caused by COPD in 2015 only, which accounts for 5% 
of all deaths globally. In the UK, the number of individuals diagnosed with COPD has 
increased by 27% in the last decade (Table 1.3) which potentially means that more undiagnosed 










Table 1.3 | Estimated cases of individuals diagnosed with COPD over the period of 
2008-2012 
Newly diagnosed cases of COPD have increased from under 1600 to approximatively 2000 
in the last decade, rising the incidence as well by 9% for the period of 2008-2012 only 





1.2.2 | Causes of COPD 
The vast majority of COPD cases are mainly caused by tobacco smoking, although specific 
occupational exposures can also represent significant risk factors (Salvi and Barnes, 2010). 
Moreover, the morbidity of COPD represents a serious social and economic burden and the 
Global Initiative for Chronic Obstructive Lung Disease (GOLD, 2014) claims that these 
increase with patient age. It is difficult to assess the precise figures of COPD morbidity, whilst 
comorbidities interfere with the respiratory condition. Mathers and Loncar (2006), argue that 
by 2030, COPD will become the fourth leading cause of mortality globally, fact that will 
employ major consequences worldwide. 
 
 
1.2.3 | Causes of COPD – Smoking  
Since tobacco smoke represents the highest risk factor for COPD, the prevalence in current and 
ex-smokers is greater compared to non-smokers (Halbert et al., 2006; WHO, 2016). According 
to the World Health Organization (WHO, 2016), COPD cases are likely to increase in the years 
to come, caused by the prevailing smoking incidence and the aging population. For this reason, 
a method to prevent developing COPD in a smoker is either by avoidance or early cessation of 
tobacco smoking. The WHO Framework Convention on Tobacco Control (WHO-FCTC) 
(2017) is trying to implement effective strategies of tobacco control and promote non-smoking 
globally. 
Previously, COPD cases were more common in men, compared to women, due to the higher 
levels of tobacco smoking (Halbert et al., 2006). However, the aforementioned is more relevant 




smoke used for cooking and heating by women in low-income countries are extremely high, 
COPD now sets both genders at an almost equal level (WHO, 2016). 
 
1.2.4 | Causes of COPD – Occupational Dusts and Fumes 
Almost 90% of COPD deaths are recorded in low- and middle-income countries due to indoor 
air pollution from solid biomass fuel smoke exposure (Salvi and Barnes, 2010; Chakraborty, 
Mondal and Datta, 2014). Workplace exposures to certain fumes and chemicals including 
isocyanates, polycyclic aromatic hydrocarbons (PAHs) and welding fumes containing iron 
with additive metals like titanium, cobalt or copper, and dusts consisting of asbestos, coal, grain 
and silica (Blanc and Toren, 2007) have been confirmed to contribute to the development of 
COPD.  
A recent evaluation of a Biobank study in the UK on the variation concerning the prevalence 
of COPD caused by certain occupational exposures, has concluded that former coal miners 
were predominant and linked to numerous cases of chronic bronchitis and emphysema (Health 
and Safety executive, 2016). Nowadays, the annual number of cases has decreased as there are 
less coal miners subjected to long periods of underground exposure.  
  
1.2.5 | Pathogenesis of COPD  
COPD is an irreversible disease caused by exposure to certain irritants and develops slowly by 
triggering an inflammatory response in the respiratory tract. The most common symptoms that 
COPD present are exacerbations characterised by dyspnoea (breathlessness), chronic cough 
and production of sputum (phlegm) (WHO, 2016). As the condition progressively worsens, 




strenuous challenge. It is very common during episodes of acute exacerbations for 
inflammatory events in the respiratory tract to increase. This may be due to colonisation of the 
lower respiratory tract by bacteria or viruses (Wedzicha and Seemungal, 2007). Moreover, a 
study conducted by Donaldson and Wedzicha (2014), indicated that seasonal variation 
represents a factor that can influence the COPD exacerbations as well. The seasonality of 
exacerbations varies with the geographical latitude, since greater cases are registered in 
countries with more temperate climates, where people are exposed more frequently to cold, 
damp conditions. This in turn, increases the level of bacterial load in the lungs of individuals 
suffering from COPD, as well as the increased prevalence of respiratory viral infections. 
Garcha et al. (2012) indicated an evident increase in the level of bacterial load in COPD 
patients with exacerbations compared to COPD patients at mild or moderate stages. This 
suggests that the microbiome – which describes the microbiological components in a 
population - plays an important role in a patient’s susceptibility to increased airway 
inflammation. Therefore, characterisation of the COPD microbiome could provide a better 
understanding on how the immune system influences the condition and could influence the 
development of better clinical strategies.  
Another aspect that plays a significant role in the symptoms of COPD is oxidative stress. 
Stanojkovic et al. (2011) considered the lung functions when assessing the oxidative stress 
parameters and inflammatory markers in 74 patients suffering from severe COPD 
exacerbations in some with ischaemic heart disease (IHD) as co-morbidity compared to 41 
healthy subjects. Results indicated a low total antioxidant status (TAS) and an elevated 
prooxidant-antioxidant balance (PAB) in COPD patients compared with individuals from the 
healthy control group. In addition, COPD patients with positive IHD recorded higher PAB 
levels in comparison to the negative IHD patients, which confirmed the Alamdari et al. (2008) 




(2011) study, validated PAB as an oxidative stress marker linked with COPD exacerbations. 
This offered more insight on how to modulate exacerbations by medical treatment. 
Subsequently, the inflammatory markers; C-reactive protein (high sensitivity C-reactive 
protein hsCRP) and the neutrophils percentages, were shown to be higher in COPD patients 
than in controls. Interestingly, there was a significant correlation between PAB and hsCRP 
(Pearson’s correlation r = 0.388, P <0.05) implying a possible link amid oxidative stress and 
inflammatory markers (Stanojkovic et al., 2011).  
Oxidant-antioxidant imbalance and elevated inflammatory markers in COPD-IHD are both 
common symptoms of end-stage diseases, which belong to the two top groups in causes of 
mortality as shown in Chapter 1.1, Table 1.2 (Doehner et al., 2009; von Haehling et al., 2009). 
This commonality in high oxidant/antioxidant levels and elevated systemic inflammation 
particularly in patients with both severe COPD exacerbations and IHD (or chronic heart failure) 
suggests that these diseases are mutually influenced. Indeed, IHD could develop gradually due 
to the influence of COPD. Therefore, antioxidant therapy constitutes a great form of auxiliary 
treatment for COPD exacerbations with regards to novel clinical therapeutic interventions. 
 
 
1.2.6 | Assessment and Diagnosis of COPD 
In the case that a person is an active or former smoker or has a history of exposure to other 
types of COPD risk factors and experiences symptoms such as shortness of breath and chronic 
cough with sputum production, the next crucial step is to carry a spirometry test (measurement 





The post bronchodilator test measures, through spirometry, the percentage between the forced 
expiratory volume in one second (FEV1) over the forced vital capacity (FVC). Therefore, the 
FEV1/FVC ratio, also termed as the FEV1% of predicted, provides the patient’s natural 
respiratory capacity status (Global Initiative for Chronic Obstructive Pulmonary Disease, 
2014). Spirometry test results are recorded before and after bronchodilator administration in 
order to establish the reversibility of airway obstruction. The bronchodilator reversibility test, 
along with the past medical history of a patient, is also significant for differentiating the 
similarities between COPD from asthma, as shown above in Figure 1.3 (Adawy, 2016). 
Based on the outcome of FEV1/FVC ratio, COPD -linked limitation of the airflow can be 
classified from mild or GOLD I, moderate or GOLD II, severe or GOLD III to very severe or 
GOLD IV. As it can be observed in Tables 1.4 and 1.5 (new GOLD stages of COPD), the more 
the airflow limitation worsens the more the FEV1 value declines.  
 
 
Figure 1.3 | Spirometry test (FEV1/FVC) standards between normal healthy lungs and 
COPD- or asthma-affected lungs 
COPD diagnosis is usually confirmed following the spirometry test (breathing test) which 
measures the breath capacity and the speed of forcible exhaled air. A ratio of the FEV1/FVC 
(Forced expiratory volume in 1 second/Forced vital capacity) result of less than 0.70 




Table 1.4 | Classification of COPD stages according to the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) 
COPD is classified into four stages depending on the severity of the symptoms that a patient 
presents. The staging criteria is established by the FEV1 of at 70% or less of FVC ratio 
(FEV1/FVC) in accordance with the patient’s medical history and other symptoms (table 




Although spirometry is the principal technique for diagnosing COPD and staging its severity, 
Jones, (2009) showed patients with the same FEV1/FVC ratios, but with different backgrounds 
varied regarding their quality of life. This suggests that the risks of comorbidities associated 
with the condition need to be taken into account when screening and diagnosing COPD 
patients, because the quality of life can have a major influence on the patient’s health status. 
 
 Furthermore, an evaluation tool that can aid in the screening of the respiratory condition is the 
COPD Assessment Test (CAT), which measures the influence of COPD on a patient’s life 
based on the changes in health status throughout time (Jones et al., 2009; CAT COPD 
Assessment Test, 2012). CAT uses a questionnaire composed of eight items that assess the 
severity of a variety of respiratory symptoms common to COPD, in relation to the patient’s 
health status. At the end of the COPD assessment, every patient obtains a score which is 
intended to provide insight of the effects that COPD symptoms have on the patient’s life. This 
can be further investigated through consultation and/or intervention. The CAT score should 





Additionally, patients at a more severe stage of COPD have frequent exacerbations and are 
more inclined to get higher CAT scores, compared to patients at a milder stage of COPD (Jones 
et al., 2009). 
 
However, crucially, the CAT questionnaire is not suitable for screening, as the diagnosis and 
severity stage of COPD can only be achieved through spirometry and/or pulmonary function 
assessment (Hanania et al., 2010).  
The new COPD GOLD staging was derived due to the validity of the mMRC test, which 
measures the dyspnoea- associated disability. The mMRC test correlates with the health status 
and is able to predict the risk of mortality. Moreover, Nishimura et al. (2002) showed that 
dyspnoea severity correlates more with mortality than the disease severity based on FEV1. As 
a result, both CAT and mMRC breathlessness tests are used in clinical settings, and this allows 
them to be easily integrated in routine clinical practice. 
Table 1.5 | New classification system for COPD severity stages according to GOLD 
guidelines 2011  
The new GOLD (Global Initiative for Chronic Obstructive Lung Disease) stages for COPD 
according to the severity of the airflow limitation, based on Post-bronchodilator FEV1 results. 
The GOLD test assessment is based on the CAT or mMRC (modified Medical Research 
Council) tests. Image retrieved from COPD Management and the 2011 GOLD Guidelines - 





1.2.7 | Treatment and Management of COPD 
A key solution to improve the management of COPD consists in adopting a healthy life-style, 
which can decrease the risk of the disease progression, lessen exacerbations and mortality 
(GOLD, 2013). Smoking cessation has also proven to be an efficient prevention method as it 
reduces the inflammatory damage that cigarette smoke is causing to the lungs (GOLD, 2014). 
However, there is no known medication that can prevent or at least reverse the progressive lung 
function deterioration that COPD causes (Cameron, 2015). 
Thus, pharmacological and non-pharmacological treatment approaches focus on dealing with 
COPD symptoms, improve lung function and quality of life. Pharmacological therapy, 
otherwise known as the cornerstone management for COPD, includes anticholinergics, long-
acting bronchodilators (2-agonists) and the most used, corticosteroids available in different 
forms including tablets, injections, inhalers or as lotions and creams (Gold Initiative for 
Chronic Obstructive Lung Disease, 2014; Respiratory Care and Sleep Medicine, 2016).  
It is required for every COPD treatment to be chosen according to every patient’s GOLD stage 
and comorbidities, otherwise it can impose serious complications, i.e. high risk of developing 
pneumonia after corticosteroid use. Therefore, increased use of rescue medication may 
aggravate the disease (Donaldson et al., 2002). 
Non-pharmacological types of medication for COPD include pulmonary rehabilitation, oxygen 
therapy or pulmonary transplantation (Global Initiative for Chronic Obstructive Lung Disease, 
2014). 
The greatest challenge in managing COPD in patients at severe GOLD stages is prescribing 




exacerbations is always poorly defined and consequently, their impact cannot be minimised 
through targeted treatment (Respiratory Care and Sleep Medicine, 2016).  
Triggers for COPD exacerbations include bacterial or viral changes or infection but also such 
as temperature changes (Wedzicha and Seemungal, 2007). So far, the most effective treatment 
for COPD exacerbations has proven to be the antibiotic use. Antibiotic treatment reduced the 
frequency of exacerbations, with enhanced results especially in patients with severe COPD 
than in those with moderate COPD.  
Comprehending the lung microbiome in COPD patients at an early GOLD stage, may offer 
new insights regarding the causes that trigger acute exacerbations in patients at more severe 
stages. 
It is important to note that COPD constitutes a driving factor in lung cancer (Durham and 
Adcock, 2015). There are fundamental predispositions such as increased oxidative stress, 
repression of DNA repair mechanisms or cellular proliferation, that could determine COPD to 
progress into lung cancer, or occur as co-morbidities.   
 
1.3 Lung Cancer 
It is now well established that cancer arises from active changes in the genome, causing 
instability and mutations that activate oncogenes and tumour-promoting inflammation leading 
to limitless replicative potential (Hanahan and Weinberg, 2000; Bishop and Weinberg, 1996). 
However, cancer in itself can be defined more as a cluster of diseases, which share similar 
characteristics, such as unregulated cell growth that eventually leads to the metastasis from the 
primary site of the tumour to other sites in the body (Cameron, 2015). Hanahan and Weinberg 
(2000) have defined these into a few indicative hallmarks, which are shared by most, and likely, 




genetic alterations trigger the progressive transformation of “normal-working” human cells 
into highly malignant derivatives. A better understanding of these hallmarks could provide 
greater results in all areas of cancer research by improving the cause, detection, epidemiology 






















Figure 1.4 | The general hallmarks of cancer throughout the formation of 
tumorigenesis 
Acquired characteristics of most, and likely, all cancers as suggested by Hanahan and 
Weinberg (2000), that present a general set of functional abilities during the process of 
their development, although through various automatic strategies. Figure retrieved 
from Hanahan and Weiner (2000). 
 
 
1.3.1 | Statistics in Lung Cancer 
In the United Kingdom, one of the high-income countries (World Bank Ranking list of 
economies, 2016), the leading causes of cancer deaths are lung, bowel, breast and prostate 




deaths, more than a fifth are due to lung cancer, with 130 new cases diagnosed every day 
(Cancer Research UK, 2014).  
Lung cancer is the leading cause of death in men and second only to breast cancer in women, 
with an increased incidence rate in people aged 75 and over (Cancer Research UK, 2014).  
In countries with emerging economies (low-to-middle-income-countries) such as China and 
India, the incidence (new cases) of lung cancer and deaths produced by the disease are rapidly 
rising due to the accelerated industrialization and urbanization, in association with incredible 
changes in life style and environment combined with the aging population (Bode et al., 2015). 
The risk factors that trigger lung cancer remain the same as in low- and middle-income 
countries, plus the addition of the eminent four shared behavioural factors that include tobacco 
use, unhealthy diet, physical inactivity, exposure to radon gas and asbestos, and the harmful 
use of alcohol (World Health Organization (WHO), 2010).  
In lines with such environmental risk factors, studies on migrant communities (Jemal et al., 
2010) have revealed that cancer rates in the descendants change towards the cancer rates of the 
host country. Thus, adopting an “unhealthy western lifestyle”, such as smoking and bad dieting 
to name a few, can eventually overcome the genetic differences between populations (Jemal et 
al., 2010). Consequently, lung cancer diagnoses have increased dramatically in the last decades 
and are predicted to become a worldwide major cause of morbidity and mortality in future 
years. As shown in Table 1.6, despite the geographical variation in cancer distribution, lung 
cancer is present within the highest numbers of new cases and deaths in both males and females 





Therefore, lung cancer is becoming one of the commonest types of cancer in both sexes, 
regardless of the financial status or geographical area. Furthermore, whilst the focus falls on 
lung cancer treatment and genetic susceptibility profiling, a greater interest is arising on 




Table 1.6 | Annual number of new cases and deaths for the ten most common types of cancer 
in accordance with the income groups and gender  
High-income countries: USA, Japan, Germany, France, United Kingdom, Italy, etc.; upper-
middle-income countries: China, Brazil, Russia, Georgia, Iran, Iraq, etc.; lower-middle-income 
countries: India, Egypt, Nigeria, etc.; low-income countries: Ethiopia, Senegal, Sierra Leone, 
Zimbabwe, etc. Lung cancer seems to prevail despite the geographical area or financial status, 
permanently situated on the first, second or third place in the commonest types of cancer (Tables 






1.3.2 | Causes of Lung Cancer – Smoking  
Our present understanding of LC as a disease relies on the prolonged exposure of pulmonary 
DNA to an array of metabolically activated carcinogens, which are further eliciting changes in 
key genes regulating cell-growth. Lung cancer statistics suggest that 30% of cases are linked 
to cigarette smoking (Global Status Report on Noncommunicable Diseases, 2010), typically in 
the more developed countries. Additionally, smoking is one of the leading causes of lung 
cancer (International Agency for Research on Cancer IARC Monographs on the Evaluation of 
Carcinogenic Risks to Humans, 2002), with the foremost indicator of risk being the duration 
(measured in pack years) rather than quantity of smoked tobacco (Cornfield et al., 2009).  
In the UK, LC mortalities indicate a high percentage, ranging between 80 – 90%, and are 
related entirely to smoking (Rossi et al., 2005; Hecht, 2002). Currently, 4000 chemicals have 
been identified in cigarette smoke, with more than 60 recognized as carcinogens by the 
International Agency for Research on Cancer (Hoffman et al., 2001). With respect to LC, the 
most threatening and harmful carcinogens are PAHs (Polycyclic Aromatic Hydrocarbons) and 
nicotine-derived nitrosaminoketone (NNK) (Hecht, 1999). Although, nicotine is not recognised 
as a carcinogen, it can still induce tumours under certain particular conditions (Schuller et al., 
1995; Hecht et al., 2000).  
However, the major role of nicotine is through addiction which motivates people continue to 
smoke despite its known adverse effects on health (Hecht, 2002). Although, each dose for every 
carcinogen per cigarette is relatively small, the cumulative dose during a smokers’ lifetime is 
substantial. For this reason, cigarettes embody a harmful nicotine device with more than 60 
carcinogens in each puff (Hecht, 2000).  
Moreover, it has been acknowledged (Wistuba et al., 1997; Hecht, 1999; Hanahan and 




associated with progressive mutations in the genome sequence. Wei et al. (2000) came to a 
similar conclusion in a study involving 732 clinical patients, half suffering from LC and half 
without (controls). This confirmed there were statistically significant differences between the 
DNA repair capacities of patients suffering from lung cancer in comparison with the control 
group. 
As only a minority of the smoking population develops lung cancer, the probability of being 
susceptible to the disease could differ from individual to individual.  There are various factors, 
which could potentially induce susceptibility to lung cancer in smokers. These factors range 
from carcinogen uptake, metabolic stimulation and detoxification, DNA repair proficiency, 
apoptosis and varying outcomes on genes included in signal transduction pathways and 
regulation of the cell cycle (Hecht, 1999; Perera, 1997). 
Differences in carcinogen metabolic stimulation and detoxification, bring to attention PAH, the 
most broadly studied carcinogen (Phillips, 1983; Hecht, 1999). Accordingly, PAH, is the 
prevalent cause of the carcinogenic effect regarding occupational exposure to soots, coal tars 
and other related materials (Phillips, 1983). Additionally, previous studies in this field have 
revealed variation amongst individuals concerning the metabolism and DNA-adduct formation 
by PAHs (Bartsch et al., 2000; Smith et al., 2001). Therefore, humans differ in respect to the 
process of PAH activation and detoxification. Moreover, individuals who are exposed to PAH 
compounds excessively are at greater risk because of its carcinogenic effects, rather than 
persons who efficiently detoxify those (Smith et al., 2001).  
In the context of human tobacco-carcinogen uptake, it is necessary to make advances in the 
comprehension of carcinogen dose and its mechanism of carcinogenesis. This in turn, can 
provide the biochemical foundation for investigating the link between exposure to tobacco 




NNK is classified as a systemic pulmonary carcinogen that generates lung tumours, as it 
reaches the lung via cigarette smoke. Consequently, NNK carcinogens can generate the 
development of adenocarcinoma, which represents the most common form of lung cancer in 
humans (Wynder and Hoffmann, 1994; Hoffmann et al., 2001). Statistics have indicated a rise 
in the amount of NKK in cigarette smoke correlated with increases in adenocarcinoma of the 
lung (Wynder and Hoffman, 1994). Additionally, these studies reveal the fact that systemic 
lung carcinogens such as NNK, are a principal cause in triggering lung cancer in humans. 
Epidemiological studies suggested cigar smokers that exhibited an increased risk in lung 
cancer, (Boffetta et al., 1999; Shapiro et al., 2000). Concurrently, it was established (Hecht and 
Hoffmann, 2000) that NNK was abundant present in cigar smoke.  
Another factor that can lead to the formation of cancerous cells in the lung is the oxidative 
stress/damage which can also be linked to smoking. Oxidative damage can be responsible for 
causing DNA lesions, such as 8-oxoguanine. The 8-oxoguanine is a mutation process resulting 
from the mismatched pairing with adenine (A); causing guanine (G) to pair with thymine (T) 
and cytosine (C) to pair with adenine which triggers substitutions in the genome (Kanvah et 
al., 2010; Paz-Elizur et al., 2003). 
The most efficient method of reducing lung cancer mortality is prevention. However, since 
preventing people from starting to smoke is not always successful so the employment of viable 
cessation techniques is needed. Cigarette smoking is not going to cease in the near future, in 
fact, there are approximately 1.1 billion smokers worldwide, consuming around six trillion 







1.3.3 | Causes of Lung Cancer - Passive Smoking 
Environmental tobacco smoke, otherwise known as second-hand smoke (SHS), is now widely 
acknowledged as one of the causes of LC. However, the risk probability is inferior to that of 
primary smokers. In the context of SHS, epidemiological studies on women with smoking 
spouses show increases in NNK to levels that were six times higher compared to women who 
lived with non-smokers (Anderson et al., 2001). Similar findings were shown with increased 
NNK in a group of economically deprived schoolchildren exposed to environmental tobacco 
smoke (ETS) (Hecht et al., 2001). Second-hand smoke can cause numerous health problems in 
infants and children, including more severe and frequent asthma attacks, respiratory and/or ear 


















 Figure 1.5 | Health consequences in children and adults associated with the exposure 
to second-hand smoke 
 It has been proved that there is no risk-free level of passive smoking. Ever since the 1960’s 
(Surgeon General’s Report, 1964), it has been established that second-hand smoke (SHS) 
constitutes one of the causes that triggers lung cancer in humans and it is responsible for the 
cause of other medical conditions, which are mentioned in this figure. The condition 
highlighted in red (Stroke), was recently linked to SHS (Surgeon General’s Report, 2014). 




Collectively, these observations support the concept of environmental tobacco smoke as a 
cause of LC, since there is a biochemical link between the uptakes of NNK by non-smokers 
when exposed to such risk settings.  
 
1.3.4 | Potential Agents that Impact the Progression of Carcinogenesis in Lung Cancer 
– Socioeconomic and Sociodemographic Causes 
In the UK, social status contributes to the increase in percentage of smokers (Bauld, 2006; 
Cancer Research UK, 2016; ASH, 2001). In addition, a study conducted by Jarvis (2001), 
showed that 55% in the affluent smokers wished to cease smoking compared to 5% of the less 
advantaged individuals. Migrant communities that live in the UK fall into this category as well. 
The figure below (Figure 1.6) illustrates the varied smoking rates among the different 
communities within the UK population. 
Additionally, ASH (2005), confirmed that smokers with a modest income consumed more 
tobacco than wealthy smokers. Smokers with routine and manual job consume on average 15 
cigarettes a day per person, whereas smokers in managerial and professional groups consume 
13 cigarettes a day. There is evidence that less affluent smokers spend a seventh of their 
disposable income on cigarettes, fact that can also determine poorer food choices. They also 
tended to smoke cigarettes with a higher tar yield, leaving a shorter stub or by drawing harder 
on the cigarette.  
Apart from the association with tobacco consumption, a polluted working environment, a poor 
diet, low income and less advantaged social backgrounds can affect as the likelihood of 








1.3.5 | Causes of Lung Cancer – Radon Gas and Asbestos  
Exposure to radon gas is, after tobacco smoke, the second main leading cause of LC and the 
principal environmental cause of LC deaths (Copes, Scott, 2007; EPA, 2009). The risk of 
developing lung cancer from radon gas exposure is 10 to 20 times higher in smokers when 
compared to non-smokers (Agency for Toxic Substances & Disease Registry, 2013). It is not 
just underground miners subjected to increased radon exposure from uranium, tin, silver or 
coal that develop LC, but households with elevated radon levels have been linked to increased 
Figure 1.6 | Smoking rates of the Black and Minority Ethnic (BME) communities 
within the UK population 
Different smoking percentages of the BME individuals that live in the UK, according to the 
General Household Survey (2005). ‘Other White’, ‘White’ and ‘Black African’, ‘Other 
Mixed’ and ‘Bangladeshi’, ‘Chinese and Other’ groups showed significant high percentages 




risk of pulmonary conditions (Field et al., 2000; Agency for Toxic Substances & Disease 
Registry, 2013).  
Asbestosis is a general term attributed to a group of minerals composed of microscopic fibres, 
which was widely used in construction in the past (NHS, 2014). This group of minerals, if 
undisturbed, does not present risk factors for individuals’ health. However, if the material 
comprising asbestos is broken, chipped, drilled or allowed in any way to deteriorate, this 
releases a fine dust composed of asbestos fibres. If the dust containing asbestos fibres is 
inhaled, it enters the lungs and gradually damaging them over time (NHS, 2014). In the case 
of prolonged exposure to high numbers of asbestos fibres, asbestosis can develop. Asbestosis 
is a recognised occupational lung disease, since most cases registered amongst people that work 
in the Construction Industry. Nowadays, asbestosis became a relatively rare condition, since 
strict regulations and precautions regarding building construction were put into place, but large 
amounts of asbestos can still be found in many older buildings. 
 
 
1.3.6 | Types of Lung Cancer 
Lung cancer (or lung carcinoma) classifies into two groups: non-small-cell lung carcinoma 
(NSCLC) and small-cell lung carcinoma (SCLC). SCLC tends to grow and spread faster than 




1.3.7  | NSCLC 
 
Approximatively 85% to 90% of LC cases are NSCLC and are usually classified in three 
subtypes: adenocarcinoma, squamous-cell carcinoma and large-cell carcinoma laid out in 
Figure 1.7 (Healthline, 2015).  
Of these, adenocarcinoma is a slow-growing type of lung cancer characterised by 
overproduction of glandular-related molecular products, such as mucin. It is the commonest 
type to occur in smokers, although it has in non-smokers as well. Squamous-cell carcinoma, 
the second most common form of lung cancer, normally occurs in the centre of the lung. The 
 
Figure 1.7 | Cytology smears of suspected cases of lung carcinoma with the aim of being 
utilized as diagnostic material 
Cytopathology of non-small-cell lung cancer (NSCLC) including adenocarcinoma, 
squamous-cell carcinoma and large-cell carcinoma, and small-cell lung cancer (SCLC) 




third type of NSCLC, is large-cell carcinoma, as indicated by its name, it is characterised by 
large cancerous cells with excess cytoplasm and a big nucleus. The large-cell carcinoma is less 
common, however it can occur anywhere in the lungs and it metastasizes rapidly (Travis et al., 
2004). 
In order to define how far the cancer has progressed, determine the prognosis and the right 
form of treatment, the NSCLC stages are assessed via the Tumour, Node, Metastases (TNM) 
structure. The TNM structure ranges from Stage 0 to IV, and it is intended to assess the primary 
tumour, the regional nodes and the progression of distant metastasis against established 
conditions (Travis et al., 2004). Additionally, Stage IV is the most severe and marks the 






1.3.8 | SCLC  
As opposed to non-small-cell lung cancer, small-cell lung cancer is less common and it 
accounts for 10% out of all lung cancer cases. SCLC tends to commence from the centre of the 
chest, in the bronchi. It has a typically distinct appearance, characterised by oval rounded small 
cells or spindle-shaped with minimal cytoplasm and poorly-defined cell edges as shown in 
 
Figure 1.8 | The Tumour, Node, Metastases (TNM) assessment structure  
The TNM structure is employed in assessments of the primary tumour, the regional nodes 




Figure 1.7. Additionally, SCLC differs from NSCLC for the reason that it has a shorter 
doubling time, higher growth fraction and the tendency to develop earlier metastases in its 
premature stages. SCLC is staged differently than the NSCLC, as limited or extensive 
depending on how far the lung cancer has metastasised. This represents the equivalent to the 
NSCLC TNM staging format (Travis et al., 2004).  
 
1.3.9 | Lung Cancer Diagnosis and Treatment  
The treatment for lung cancer patients varies with the lung cancer type, stage at diagnosis and 
treatment. One major issue in the proper treatment is the ability to correctly diagnose the type 
of lung cancer and its stage, in order to choose the suitable treatment type. Identifying the 
correct lung cancer diagnosis and/or stage can be very difficult, since the symptoms of the 
condition resemble other less serious respiratory conditions. Therefore, the pre-clinical 
diagnosis of lung cancer based on the observed symptoms can be misidentified with those of 
other pulmonary diseases (Healthline, 2015).  
At the moment, there is no evidence of any method aimed to detect lung cancer in 
asymptomatic patients. Moreover, current methods of early detection of lung cancer can show 
unclear results or false positives and negatives (Cameron, 2015). This in turn, creates 
consequences for patients, causing them psychological distress, which leads to increased 
anxiety caused by the respiratory condition (Byrne et al., 2008). However, survival rates in 
lung cancer are higher for Stages I and II, given that the prognosis is really poor and only 10% 
of patients remain free of disease (Healthline, 2015). The five-year survival rate registers such 
a small percentage due to late diagnosis, when the cancer is so advanced that surgical 
intervention or other clinical involvement proves to be ineffective (Baldwin et al., 2011). 




1.3.10 | Screening for Lung Cancer  
Currently, screening techniques for lung cancer have proved to identify patients at high-risk of 
developing the disease by using three methods: physical examination, spiral computerized 
tomography (CT) scan and biopsy assessment. 
 
1.3.11 | Screening for Lung Cancer – Medical Examination  
The medical examination focuses primarily on signs of cough (chronic or recurrent) or 
coughing up phlegm that contains blood, chest pain and shortness of breath, wheezing or other 
potential symptoms that indicate the presence of LC in a patient. The patient’s history of 
smoking and a chest X-ray typically in the form of a CT scan, also have to be included in the 
physical examination (OnHealth, 2016).  
 
1.3.12 | Screening for Lung Cancer – Spiral CT Examination 
This technique of CT scanning constructs detailed images of the body internally. Hence, when 
coupled to an X-ray machine it generates 3D images of the patient’s internal organs where 
potential cancerous tumours may be revealed (OnHealth, 2016).  
Study trials based on the efficiency of CT scans, carried in different countries, have given 
inconclusive results. A Japanese research study conducted by Nawa et al. (2012) on low-dose 
CT (LDCT) scans concluded that out of a total of 61,914 CT scans, 25,385 patients were 
screened for lung cancer and only 210 individuals were identified with primary lung cancer. 
Within these 210 patients, 203 underwent surgery with an outcome of 90% success regarding 
the five-year survival rate for all patients. Consequently, CT scans constitute an effective 




scans to identify merely 0.83% of individuals suffering from lung cancer might prevent its 
implementation in a national screening procedure, due to cost.  
Similarly, an Italian study (Infante et al., 2009), confirms that spiral CT scans may be over-
estimated. In addition, spiral CT scans identified a large number of Stage I lung cancer patients 
in comparison to its randomised control group. However, in the three-year follow-up 
assessment it was confirmed that there has been minor variation between the survival rates of 
lung cancer cases identified through spiral computed tomography and those detected using 
conventional means. 
At best, the screening process based on spiral computed tomography scan detects 
approximatively 30% of lung cancers, which leaves the majority of 70% cases undetected 
(OnHealth, 2016). If the potential of screening through CT scans does not meet the expected 
outcome of detecting lung cancer at early stages, the next steps are biopsy sample examination 




1.4 | Pneumonia  
A general consensus has defined pneumonia (or pneumonitis) as a group of acute (co)infections 
of the lung parenchyma (lung sections such as alveoli or the air sacs involved in gas transfer) 
that is caused by various pathogens. It is usually considered separately to bronchiolitis due to 
its well-defined symptoms (Mackenzie, 2016).  
Pneumonia is associated with an inflammation of the lungs, specifically in the alveoli that fill 
up with fluid, causing difficulties in their normal function. Due to the intense stress received 




exterminate the foreign body; however, their accumulation can impose other difficulties for the 
lungs to deliver oxygen into the bloodstream (British Lung Foundation, 2012). 
The issue of defining and classifying pneumonia has been problematic often resulting in 
experimental or unnecessary use of antimicrobials that cause life-threatening pathogen 
resistance or contributing to heterogeneous pathologies and biased classification amongst 
clinical phenotyping (Mackenzie, 2016). To reduce the threats of the widespread empirical use 
of antibiotics and maximizing the validity of clinical studies, Levinson (2001), suggested that 
the selection of individuals for study groups should be less generalised. Therefore, patients 
should be selected that share similar clinical phenotypes and to increase the effectiveness and 
internal validity of the clinical study. For instance, a research study based on the evaluation of 
different antibacterial therapies in patients suffering from pneumonia, should be based only on 
patients with a proven bacterial cause; as opposed to using patients with viral pneumonia. 
If the methods to determine the aetiology of pneumonia are improved and the clinical studies 
focus more on subjective methods of classification, perhaps research questions regarding the 
diagnosis and management of pneumonia would deliver clearer answers. 
 
1.4.1 | Pneumonia Statistics 
Approximately 220,000 people are diagnosed with pneumonia each year. In 2012, a higher 
proportion of individuals were identified with pneumonia, particularly in the East Midlands 
and the North West of England (due to industrialization) than in the UK overall. On the other 
hand, Scotland, Wales and the other regions of England, indicated lower proportions as 
displayed in Table 1.7 (British Lung Foundation, 2012). 
With regards to the gender proportions, the British Lung Foundation (2012) indicated an 




from the period of 2004 when the maximum rate was of 292 males and 321 females per 100,000 
people. The high prevailing cases of pneumonia in women may be caused by a viral strain of 
the disease, which tends to be more severe in pregnant women and in those suffering from heart 
diseases, where female cases predominate (Dallas, 2013; Diseases and Conditions, 2016). 
 
 
In principle, pneumonia can affect people in any age group, although the most frequent cases 
are registered in children younger than five years old and in the elderly people with ages over 
60 (British Lung Foundation, 2012; WebMD, 2016). Smokers or those that suffer of other 
respiratory diseases, heart, kidney or liver diseases are susceptible as well (WebMD, 2016). 
Pneumonia cases are more common during autumn and winter and are influenced by the cold 
changes in temperature or damp weather conditions, which provide the perfect environment 





Table 1.8 illustrates the most predisposed age groups of people to develop pneumonia during 
the period of 2008-2012 with a total of 473 new cases per 100,000 amongst young children 
aged 0-5, 843 for every 100,000 in adults between 71-80 years old and 1,838 per 100,000 in 
old individuals aged 81 and above (British Lung Foundation, 2012).  
 
Table 1.7 | Total number of individuals diagnosed with pneumonia for every 100,000, over 
the period of 2008-2012  
The majority of pneumonia cases prevail in regions of England such as: West and East 
Midlands, North East, North West and in Yorkshire and Humber (colour coordinated arrows 
marked according to every region mentioned). Scotland and Wales, as well as other regions of 







As a disease, pneumonia is not contagious, although a healthy person becomes susceptible after 
coming in contact with the pathogens of an ill individual by breathing in droplets from coughs 
or sneezes, or even getting in contact with the environment that contains the pneumonitis 
viruses or bacteria. For this reason, pneumonia mortality rates indicated this disease as one of 
the three major respiratory causes of death in the UK, after lung cancer and COPD (Figure 1.1). 
Additionally, during the period of 2001-2010 approximately 214 individuals per every million 
died from pneumonia in the UK, leaving the country just outside the top of 20 countries with 
deaths. The only European countries that indicated higher mortality percentages in pneumonia 
than the UK were Slovakia and Romania (British Lung Foundation, 2012). 
 
 
Table 1.8 | Age group classification of people in the UK that developed pneumonia 
over the period of 2008-2012  
The prevailing cases of people that died from pneumonia during 2008-2012. Most 
predisposed age groups of people to develop pneumonia are children below age 5 and 






1.4.2 | Causes of Pneumonia  
More than 30 pathogens including bacteria, viruses and fungi have been found to cause 
pneumonia. The latency period of pneumonia is relatively short, the foreign organism will 
rapidly cause inflammation of the lung alveoli triggering the production of fluid and pus, as the 
person will become visibly ill experiencing chills, fever, coughing and difficulty in breathing 
(Pneumonia Symptoms and Causes, 2013). 
Pneumonia is not considered a contagious disease, although its causative pathogens are 
extremely dangerous because they are found in the commonest places or in environments that 
people frequent on a daily basis. For instance, children that attend school or day-care centres 
are more predisposed to catching viruses from each other, which increases their chances of 
developing viral pneumonia. Additionally, the viral strains causing pneumonia are more 
transmissible and likely to spread from one another in comparison to its other bacterial and 
fungal sources. An easily transmissible bacterial strain causing pneumonia is Legionella 
pneumophila. This species is transmissible only in specific environments for example, in 
certain contaminated air conditioning system. Studies have also indicated that inhaling droplets 
from spas, fountains or whirlpools may be linked to contamination with the bacterial strain of 
pneumonia as well (Pneumonia Symptoms and Causes, 2013). 
 
1.4.3 | Types of Pneumonia – Bacterial 
The most recognized species causing bacterial pneumonia include: Streptococcus pneumonia 
(pneumococcal pneumonia) extremely common in adults; Legionella pneumophila 
(Legionnaire’s disease); Mycoplasma pneumonia which affects young adults with occupations 




pneumonia which is milder and common in people over the age of 60; Haemophilus influenzae 
type B usually seen in children with ages below five years old.  
The majority of bacterial pneumonias are pyogenic (increased mucus production), therefore 
symptoms as cough with phlegm (usually thick yellow) production represents a typical sign of 
bacterial pneumonia. From this, a series of other symptoms are triggered, such as pain when 
coughing or inhaling deeply, breathlessness and exhaustion, high fever and loss of appetite 
(Pneumonia Symptoms and Causes, 2013; WebMed, 2016).  
More advanced studies (Marrie et al., 2000; Steel et al., 2013) have concluded that community-
acquired pneumonia (CAP) caused by Streptococcus pneumoniae (or the pneumococcus) is the 
leading cause of morbidity and mortality linked to pneumonia. Regardless of the efforts on 
implementing the pneumococcal polyvalent vaccine as a national strategy of immunization for 
people at high-risk, S. pneumoniae is still the commonest cause of CAP. Hospital-acquired 
pneumonia, fits under the subdivision of CAP as it particularly refers to the transmission of 
pneumonia to a patient, whilst being admitted for a different condition. S. pneumoniae has also 
been linked to other medical conditions such as septic shock, requirement for vasopressors, 
mechanical ventilation and consequently for an extended period of hospitalization in ICU (Rice 
et al., 2012). Moreover, serotype 3 was identified as a cause in triggering the invasive 
pneumococcal disease (IPD) and also associated with septic shock. In the attempt of 
understanding the microbiology of the pneumococcal infection, studies have focused on its 
serotypes severity with the aim of creating novel types of pneumococcal conjugate vaccines 
(Ahl et al., 2013).  
CAP has become one of the most dangerous infectious diseases in many parts of the world 
(Brown, 2012; Fauci and Morens, 2012; File and Marrie, 2010; Welte et al., 2012). The risks 




Several clinical studies (Ho et al., 2006; Fuller et al., 2005) have acknowledged that the 
pneumococcal bacterial load is linked to the severity of infection and has predictive value. 
Consequently, repeated measurements of the bacterial load based on reliable assays could aid 
in a more accurate technique of monitoring the treatment progress of CAP.  
 
 
Advanced clinical studies based on the biomarkers capacity to identify inflammatory markers 
in patients with CAP, were associated with WBC count, acute phase reactants such as C-
reactive protein (CRP) also identified in patients suffering from COPD, cytokines such as 
interleukin-1 (IL-1) and tumour necrosis factor- (TNF-), cortisol and stress hormones 
(Kolditz et al., 2013; Pereira et al., 2012). Of these, the ones that have received particular 
attention and have been mentioned in many research studies are the C-reactive protein (CRP) 
and procalcitonin (PCT). Additionally, CRP and PCT have been reported as useful tools of 
assessment in determining the severity of CAP and if utilised in combination with other scoring 
evaluation systems such as CURB-65, could increase the diagnosis accuracy not only amongst 
the different strains of pneumonia, but for other respiratory diseases that are characterized by 
similar symptoms (Pereira et al., 2012; Lippi et al., 2011; Steel et al., 2013).  
 
1.4.4 | Types of Pneumonia – Viral  
Viral pneumonia is usually identified in children with ages below five and accounts for 
approximately a third of all pneumonia types. Although the viral strain of pneumonia is less 
severe and mends in a few weeks, it can leave the individual more susceptible to bacterial 




experience a sore throat, loss of appetite, fever or muscle pain. One major symptom difference 
that differentiates viral pneumonia from the bacterial type is the nature of the cough that is dry, 
hence, lacks mucus production. Viral pneumonia, usually caused by the respiratory syncytial 
virus (RSV) and occasionally it can be triggered by influenza (Pneumonia Symptoms and 
Causes, 2013). 
In 2003, a new type of viral pneumonia, severe acute respiratory syndrome (SARS) was 
identified, which was triggered by the same type of viruses that produce the common cold. 
About 8,000 cases of SARS were reported at the time, but since then the incidences have 
become less common (Pneumonia Symptoms and Causes, 2013). 
 
1.4.5  | Types of Pneumonia – Fungal 
 The least common type of pneumonia and rarest in the UK, is the fungal one. According to the 
literature, there are three species of fungi (living in soil) that have been responsible for causing 
pneumonia: Coccidioidomycosis (Galigiani, 1993), found in South-West of America; 
Histoplasmosis (Deepe Jr, 2018)  and Cryptococcus (Soltani et al., 2013) found in bird 
droppings.  
Fungal pneumonia appears to often be related to the degree of weakness of the immune system 
and any virulent pathogenic mechanism(s). For example, the Pneumocystis jirovecii fungus has 
been found to cause pneumonia in patients suffering from human immunodeficiency virus 







1.4.6 | Treatment and Management of Pneumonia  
Pneumonia diagnoses usually involve physical examination, chest X-rays, cytology of a 
phlegm sample, a blood test of the patient and investigation of the medical history (Pneumonia 
Symptoms and Causes, 2013).  
For patients with milder cases of bacterial pneumonia that present a low probability of 
worsening are usually treated with a course of antibiotics along with a rest at home and to 
keeping hydrated at all times.  
Patients that suffer from more severe cases of bacterial pneumonia are often infected with 
strains exhibiting antibiotic resistance. This issue has been most often encountered in patients 
CAP caused by S. pneumoniae. In such situations, the virulence of the pneumococcus coupled 
with the inflammatory responses that it elicits, contribute to the disease invasiveness and 
symptom development.  
 
Prior to any action being taken or drug administration, every patient suspected with the 
pneumococcal infection, is evaluated using the Pneumonia Severity Index (PSI) or CURB-65 
to indicate the seriousness of the illness (Niederman, 2007; Kolditz et al., 2013). The PSI aims 
to assist in identifying patients that suffer from the bacterial pathogen and can still be managed 
at home. It is based on 20 variables such as patient age, gender, existence of comorbid 
conditions, vital signs abnormalities and several analyses of laboratory and radiographic 
parameters (Feldman, 2007). The CURB-65 on the other hand, was designed to document more 
severely ill patients, with particular interest for those admitted in the intensive care unit (ICU) 
(Pereira et al., 2012). CURB-65 contains only five variables including the levels of serum urea 




mmHg or diastolic 60 mmHg), the age threshold 65 years and the confusion level (Feldman, 
2007; Steel et al., 2013). 
Furthermore, in terms of CAP this can be complicated both seasonal and pandemic influenza 
(Steel et al., 2013). Indeed, co-infections with influenza strain H1N1 have been detected in 
patients who were initially admitted to the hospital only with CAP (Cilloniz et al., 2012). 
Pneumococcus has proven to be the most prevailing bacterial species in co-infections (62% of 
cases) (Rice et al., 2012).  
 
Due to its life-threatening nature, treatment of CAP and more specifically the pneumococcal 
disease also involves adjunctive anti-inflammatory therapies in order to suppress the pathogen-
activated inflammatory damage to the lungs (Steel et al., 2013). Three anti-inflammatory 
agents may be employed: macrolides, corticosteroids, and statins (Feldman and Anderson, 
2009; Steel et al., 2013).  
Macrolides possess both pathogen- and host-directed anti-inflammatory properties. These can 
inhibit bacterial protein synthesis and secondarily, unrelated to their antibacterial activity, 
macrolides control the recruitment and mobilisation of neutrophils by reducing the production 
of neutrophil-mobilising chemotactic cytokines interleukin-8 (IL-8), interleukin-17 (IL-17) 
and tumour necrosis factor (TNF). Macrolides have been proved to have a beneficial 
therapeutic role with respect to pathogen- and host-directed anti-inflammatory activities in a 
few chronic respiratory diseases as well, such as cystic fibrosis and COPD (Steel et al., 2012). 
Corticosteroids (CS) comprise a broad range of anti-inflammatory agents, although their 
adjunctive role in patients suffering from severe CAP remains to be confirmed (Steel et al., 
2013). A retrospective study on patients with severe CAP that received systemic CS for a 




Subsequently, Meijvis et al. (2011), in a large randomized, double-blinded, placebo-controlled 
study based on low dose systemic administration of dexamethasone (corticosteroid medication) 
to non-immunocompromised patients, demonstrated a significant decrease of the 
hospitalization period. The effectiveness of corticosteroids in patients with CAP appears to be 
influenced and determined by the pathogen type with, S. pneumoniae most responsive to its 
effects (Meijvis et al., 2011). 
Statins refer to a class of pharmacological inhibitors of the enzyme 3-hydroxy-3-
methylglutarylmcoenzyme A reductase. This enzyme has cholesterol-lowering properties; 
therefore, it is utilised to regulate hypercholesterolemia to reduce the risk of cardiovascular 
diseases and stroke in people. It has been established that this statin also possesses important 
anti-inflammatory capacities (Steel et al., 2013). Several systematic studies in the field 
(Corrales-Medina and Musher, 2013), have reported improved outcomes and reduction in 
mortality by 50% in patients suffering of pneumococcal CAP after the administration of statins 
(Steel et al., 2013). This suggests that statins protect against the invasiveness and pro-
inflammatory activities in diseases caused by S. pneumoniae.  
 
To conclude, there is a clear need for improved strategies of determining the prognostic 
indicators of pneumonia and its microbial causes in order to establish more accurate diagnoses. 
This in fact, could reduce the excessive use of antibiotics, and hence, moderate the bacterial 








1.5 | Asthma 
 Asthma has been defined as a common, long-term respiratory disease that entails ongoing 
management depending on its severity. It can affect all age groups but most often, asthma starts 
during childhood (British Lung Foundation, 2012; World Health Organization, 2012.). 
Asthma is characterized by inflammation of the lung airways that can easily become irritated 
due to a series of factors such as cold air, exercise, stress, inhalation of certain substances (i.e. 
smoke), pollution or pollen (British Lung Foundation, 2012). The usual symptoms are 
shortness of breath and the feeling of a “tight chest”, cough and wheezing. During an asthma 
attack, the feeling of “tight chest” is actually caused by the swelling of the lining of the air 
passages which restricts the airways and as a consequence, the air flow that circulates in and 
out of the lungs is reduced (World Health Organization, 2012). Asthma symptoms tend to 
become more severe at night, particularly in the case of those that do not manage the respiratory 
condition properly. This in fact, is a consequence of the body’s natural process of suppressing 
inflammation (of the airways as well) that tends to switch off or decelerate while an individual 
is asleep (Asthma UK, 2015). 
 
Asthma symptoms can range from mild, which means that the person affected will experience 
it occasionally with very few symptoms, to severe asthma, in ~ 5% of cases, and these require 
medical assistance and support in order to manage the symptoms. Unfortunately, asthma 
attacks are mainly caused by people’s negligence in either taking medicines or failing to follow 
the correct medical treatment (Asthma UK, 2015). 
 
Based on the factors that trigger the condition, asthma has been categorised into two types: 




animal hair or dust mites. Conversely, the common factors that cause the non-allergic asthma 
symptoms include colds and flu produced by the cold weather, intense exercise, or irritants as 
cigarette smoke and car exhaust fumes (Asthma UK, 2015). 
 
1.5.1  | Statistics of Asthma 
 In the UK, around eight million people have been identified with asthma over the period of 
2004-2012, according to the British Lung Foundation (2012). However, statistical studies 
indicate that asthma may be over-diagnosed and new methods of identification are needed in 
order to differentiate the people that are living with asthma and are still receiving medication 
for it, from the ones that were diagnosed during childhood and grew out of it, or ceased their 
treatment despite the continuous symptoms occurrence.  
As shown in Table 1.9, between 2008 and 2012 the number of people for every 100,000 that 
have been identified with asthma indicated high rates in all parts of the UK. Although the more 
cases were seen in the East Midlands, the East of England as well as the North West and South 
West in comparison with the other parts of the UK. 
Considering the prevalence of asthma, it has been suggested that women are more affected by 
the disease than men (British Lung Foundation, 2012). Between 2008-2012 statistical tests 
indicated 284 per 100,000 new cases of asthma in women, as opposed to 261 for every 100,000 
in men. One factor that influences this could be the rate of obesity that also appears to be 
increasing faster in women than in men (Chen et al., 2002; Nystad et al., 2004).   
Nystad et al. (2004), showed that there is a link between the BMI (weight (kg)/height (m)2) of 
a person and the probability of developing asthma symptoms in a longitudinal assessment of 
135,000 Norwegians with ages ranging from 14 to 60 years old. Based on the Cox proportional 




education and physical activity with the aim of estimating the relative risk of asthma in relation 
to these variables. Contrasts between men and women with a BMI of less than 25 to the ones 
recorded as overweight (BMI = 25-29) and obese (BMI ≥30), showed relative asthma risks for 
the latter two categories. The final outcomes revealed proportions of 1.27 with a 95% 
Confidence Interval (CI) of 1.13 in men and 1.43 in women with BMIs of less than 25; 1.30 in 
overweight people (95% CI: 1.17 men, 1.45 women) and 1.99 (95% CI of 1.67 men, 2.37 
women) in people recorded as obese (BMI ≥30). The investigation findings confirmed that the 
risks of asthma increase, as the BMI gets higher with an average of BMI 20 in men and 22 in 
women across the proposed strata of smoking status, education and physical activity.  
Consequently, obesity represents a risk factor in the development of asthma in both men and 
women and can be influenced by the quality of life-style as well. 
 
Regarding the mortality in people with asthma in the UK, the figures are lower, compared to 
other respiratory diseases suggesting that asthma is easier to manage. This stated around 1,200 
people a year die of asthma (British Lung Foundation, 2012) which should raise more 




Table 1.9 | Number of individuals per 100,000 identified with asthma in the UK over 
the period of 2008-2012 
The prevailing rate of people identified with asthma tends to be higher in specific parts of 
the UK such as the East Midlands, the East of England, the North West and the South 
West, with lower cases indicated in Northern Ireland, Scotland, North East and London 




1.5.2  | Management of Asthma  
Concerning the guidelines on asthma management, there is a constant effort to improving the 
flexibility of the medication in order to make it more appropriate according to the severity type 
and responses to medical intervention in every individual. This patient specific response to 
treatment has been demonstrated in a randomised double-blind, parallel-group test has 
considered patients with asthma that were still experiencing symptoms, regardless of the 
administered dose of inhaled corticosteroids (Greening et al., 1994). The asthmatic patients 
were divided into three groups according to the medication received: the first group were given 
inhaled beclomethasone dipropionate (BDP), the second group salmeterol xinafoate and BDP, 




of every patient were measured three times a day, every day for six months. Results indicated 
an improvement in the morning measurements of the PEF in patients that received 
salmeterol/BDP and the ones that received a higher dose of BDP. Although, the increased peak 
expiratory flow at all time points was observed only in those given salmeterol/BDP with the 
occasional rescue use of the bronchodilator salbutamol (Greening et al., 1994). 
The Global Initiative for Asthma (GINA) formed in 1993, disseminates information regarding 
the management of patients with asthma, based on the published clinical literature.  The report 
“A Global Strategy for Asthma Management and Prevention” published in 1995 and 
reconsidered in 2006, to inform numerous national guidelines with respect to asthma control 
and management as the focus for the treatment choice. Another two factors emphasised in 
GINA, were the significance of the patient – caregiver relationship and guided self-
management (Bateman et al., 2008). 
However, the Asthma Insights and Reality in Europe (AIRE) survey conducted by Vermeire et 
al. (2002) assessed the prevalence of asthma control in patients from Western European 
countries as France, Germany and the UK, suggested that the GINA guidelines did not meet its 
objectives. According to Vermeire et al. (2002), the symptoms in both adults and children 
suffering from asthma were poorly controlled due to poor implementation of disease 
management plans by more than 50% of adults and 61% children in all countries.  Follow-up 
visits never occurred unless asthma symptoms worsened or for the required prescription of 
inhaled corticosteroids or short-acting bronchodilators.  
That is why there is a constant need for further efforts to thoroughly employ the importance of 






1.6 | Idiopathic Pulmonary Fibrosis (IPF) 
Idiopathic pulmonary fibrosis (IPF) has been defined as a progressive lung condition that 
deteriorates the lungs with time. Pulmonary fibrosis is characterised by the development of 
scar tissue in the lungs, causing them to become rigid and lose their elasticity when expanding, 
which consequently leads to serious breathing problems such as breathlessness of exertion, 
increased cough and dyspnoea as well as finger clubbing. The idiopathic term indicates the 
unknown aetiology from which IPF arises, making it difficult to predict its progress since it 
occurs spontaneously. Even when the condition has been stabilized, it has been shown that 
people can get sudden outbreaks of acute exacerbations. The diagnosis of IPF can be achieved 
through a chest X-ray sometimes followed by a CT scan for a more in-depth image of the lungs, 
breathing test measurements or a bronchoscopy which allows the specialist to view inside the 
lungs and obtain a small sample of the lung tissue for biopsy (British Lung Foundation, 2012). 
Idiopathic pulmonary fibrosis is an irreversible respiratory condition, which affects the alveoli 
(air sacs) by limiting the volume of oxygenated blood, which is intended to supply the lungs 






1.6.1 | Statistics in Idiopathic Pulmonary Fibrosis 
According to the British Lung Foundation (2012), approximately 6,000 individuals are 
diagnosed with IPF every year in the UK with a rate of 85% of diagnoses recorded in people 
over 70, mostly prevailing in men. The higher incidence of IPF in men compared to women 
(Nalysnyk et al., 2012) is a consequence of men being more exposed to environmental factors 
linked to working labour (British Lung Foundation, 2012). A history of occupational and 
environmental fibrogenic exposures as inhalation of mineral dusts including coal, asbestos, 
silica, beryllium (found in mineral rocks), hard metal (cobalt) or a prolonged history of 
ingestion of pharmaceutical substances such as nitrofurantoin and amiodarone may also 
constitute factors that cause IPF (Khalil et al., 2007). 
 
Figure 1.9 | Illustration of the brief anatomy of the lungs and the development of idiopathic 
pulmonary fibrosis (IPF) 
 (A) The air inhaled through the mouth and nose is drawn into the trachea, which divides into two 
bronchi that are linked to the lungs. The air then travels down the bronchi and into smaller airways 
called bronchioles. Bronchioles are formed of small air sacs called alveoli, which move the 
oxygen across small blood vessels and finally into the blood. (B) Following, the alveoli exchange 
the waste gas and carbon dioxide from the blood with the inhaled oxygenated air. In the case of 
IPF, the scarring of the alveoli can reduce the volume of inhaled air that is needed to oxygenate 
the blood and consequently causes the symptom of breathlessness (dyspnoea) in a person (British 




1.6.2 | Causes of Idiopathic Pulmonary Fibrosis  
The body generates fibrosis in response to factors that damage the lungs (Panos et al., 1990). 
The histological equivalent to IPF is interstitial pneumonia, both of which are characterised by 
scarring of the lung (fibrosis) combined with healthy alveolar tissue. This is caused by 
repetitive episodes of lung injury, which finalise in abnormal lesion recovery responses. The 
hypothesized types of injury are believed to be immunological, microbial or chemical, also 
including the aspirated gastroesophageal reflux (GER). Consequently, some individuals are 
predisposed to IPF, through repeated steps of microaspiration of gastric refluxate (Fahim et al., 
2010). Certain viruses have been also identified to contribute to the development of IPF, 
including the Epstein-Barr virus (EBV) responsible for causing glandular fever (Sitki-Green et 
al., 2004), the oral virus herpes simplex (HSV-1) and hepatitis C virus (HCV) (British Lung 
Foundation, 2012). 
A well-defined classification criterion for IPF and a possible gold standard test may provide a 
clearer understanding of the pathogenesis of the disease and therefore, provide a better 
understanding that IPF encompasses. 
 
1.6.3 | Treatment and Management for Idiopathic Pulmonary Fibrosis 
Due to the irreversible nature of idiopathic pulmonary fibrosis, current treatments only achieve 
a slower rate of the lung scarring, unable to prevent it. Currently in the UK, IPF treatments 
have increased the survival rate from untreated situations where life expectancy in individuals 
diagnosed with IPF was lower than three years due (British Lung Foundation, 2012).  
Patients may receive treatment depending on the IPF causes and severity. One approach is 
pulmonary rehabilitation, which is usually tailored according to every patient and may or may 




Pulmonary rehabilitation is a maintenance exercise programme for patients who remain 
symptomatic despite the treatment or suffer from a pulmonary impairment (Respiratory Care, 
2002) with the aim of teaching them how to handle their respiratory condition (British Lung 
Foundation, 2012). 
In more severe cases of IPF, patients require the home oxygen therapy. The oxygen treatment 
is based on a portable cylinder, which can be easily operated even from home. The aim of the 
home oxygen therapy is to increase the oxygen level in the lungs and thus, in the bloodstream 
in order to avoid heart or brain damage. Additionally, N-acetyl-cysteine (NAC) has proven to 
be of great help in reducing the mucus secretion in the lungs (British Lung Foundation, 2012). 
The current pharmacologic treatments licensed to be used in patients suffering from IPF are 
pirfenidone and nintedanib. These two medicines act by decelerating the progress of the fibrotic 
tissue in the lungs (British Lung Foundation, 2012) most likely through their action on vascular 
endothelial growth factor (VEGFR) and fibroblast growth factor (FGFR) receptor. 
 
Recent studies in the field (Flynn et al., 2015) have approached the challenging problem of IPF 
management via biomarkers that could provide early prediction of the disease. Biomarker 
candidates found in culprit cells or genes from biofluids such as saliva, blood or urine have 
provided a better insight of the IPF pathogenesis. Moreover, IPF biomarkers possess the ability 
of revealing the natural course of the disease without influencing it, as opposed to medical 
treatment.  
A group of effective indicators of IPF fibrotic are the metalloproteinases (MMPs). These zinc-
dependent enzymes are actively involved in hydrolysing components of the extracellular matrix 
(ECM) and they represent an essential key factor in biological processes as organogenesis or 




2003; Flynn et al., 2015). Metalloproteinases are the enzymes responsible for the degradation 
of the ECM. Therefore, dysregulations in the composition, structure, rigidity and abundance of 
the ECM caused by the MMPs, may be the factors that contribute to the development of fibrosis 
and invasive cancer, or other pathological conditions (Bonnans et al., 2014). MPP have also 
been shown to play an important role in the imbalance of the collagen turnover in fibrotic lung 
diseases. An evaluation study of the MMP levels has identified that particular matrix 
metalloproteinases such as MMP3, MMP7, MMP8 and MMP9 were more increased in the 
bronchoalveolar lavage fluid (BALF) of patients with IPF compared to the healthy controls 
(McKeown et al., 2009). Moreover, MM7 has been indicated to exhibit a higher degree of gene 
and protein expression in the alveolar and bronchiolar cells of fibrotic lungs (Zuo et al., 2002). 
Similarly, MMP8 and MMP9 were linked to the rapid decline of the lung function and high 
incidence in mortality (Craig et al., 2014).  
Overall, MMP7 has proven to hold an excellent clinical utility as a potential biomarker in 
monitoring the development of idiopathic pulmonary fibrosis, and in combination with other 
biomarkers of IPF, MMPs may have a role in the prognosis and disease progression of 











1.7 | Bronchiectasis 
Bronchiectasis is an irreversible respiratory disease characterised specifically by inflammation 
of the airways (bronchi) and build-up of mucus, which eventually become infected due to 
bacterial accumulation. In cases where bacteria subsist in the airway tubes, these become 
inflamed and consequently result in respiratory impairment (British Lung Foundation, 2012). 
 
1.7.1 | Bronchiectasis Statistics 
According to the British Lung Foundation, in 2012, approximately 210,000 individuals in the 
UK were suffering from bronchiectasis. However, the high incidence of bronchiectasis requires 
more thorough statistical measurements to confirm the existing information and to establish 
whether the disease is becoming more common or is being identified more accurately. 
Bronchiectasis is most common in the West Midlands more than any other region in the UK, 
with the lowest rate identified in the South East of England (British Lung Foundation, 2012) 
(Table 1.10). 
In the recent years, there appears to be an increase of 33 per 100,000 of newly diagnosed 
individuals with bronchiectasis in women compared to men. Most people affected by 
bronchiectasis are aged 70 or over which accounts for 60% of all patients. Bronchiectasis 
accounts for 0.3% of all deaths in the UK and 1.4% of deaths caused by lung disease (British 
Lung Foundation, 2012). 
 
1.7.2 | Causes of Bronchiectasis  
Similarly to IPF, the causes that trigger bronchiectasis remain unknown, yet the consequences 




respiratory diseases can also lead to bronchiectasis, whether a severe lung infection during 
childhood, such as pneumonia, allergic responses associated with asthma, or in comorbidity 
with cystic fibrosis (characterised by production of thick mucus) and gastric reflux (British 
Lung Foundation, 2012). 
Due to its symptoms of frequent sputum production, dyspnoea and wheezing, bronchiectasis 
can be easily linked with COPD or mistaken for COPD, which imposes extra urgency in the 
correct diagnosis of the disease and in choosing the most appropriate treatment.  
 
Table 1.10 | Individuals diagnosed with bronchiectasis over the period of 2008-2012, in 
the UK 
The highest incidence of bronchiectasis cases was registered in the West Midlands of the 
UK, as opposed to South East of England, which indicated the lowest prevalence of the 







People suffering from bronchiectasis are more prone to bacterial infections due to the mucus 
accumulation in the bronchi, which consequently worsens the symptoms, sometimes resulting 
even in haemoptysis (coughing up blood), chest pain and inflammation of joints. 
Individuals suspected of bronchiectasis, usually undergo a computerised tomography (CT) 
scan or CAT scan, in order to confirm the unusual widening of the airways and the diagnosis. 
Further cytological tests of a sputum sample may be required to identify the existence and type 
of bacteria present in the mucus and a blood test that may reveal the potential causes of 
bronchiectasis (British Lung Foundation, 2012). 
 
1.7.3  | Treatment and Management of Bronchiectasis  
Given the fact that bronchiectasis is an irreversible disease the available treatments aim to 
prevent additional damage and reduce the symptoms in order to improve the patients’ quality 
of life. Bronchiectasis infections are treated with antibiotics, usually through oral 
administration in tablet form or inhaled through a nebuliser.  
An alternative approach is pulmonary rehabilitation based on breathing exercises and methods 
that facilitate the reduction of sputum build-up in the lungs. If pulmonary rehabilitation does 
not meet its requirements, instead there are pharmacologic agents for mucus clearance. These 
consist of a hypertonic saline solution concentrated into nebulisers or Carbocisteine inhaler 
devices with the aim of maintaining the airways hydrated and facilitating the expectoration of 
mucus from the lungs (British lung Foundation, 2012). 
Studies conducted on patients at a stable phase of bronchiectasis, have concluded that local and 





Additionally, evaluations of CT scans, lung function and health related quality of life (HRQoL) 
in bronchiectasis patients, have indicated increased levels of inflammation markers in their 
total white cell count, neutrophils and C-reactive protein levels. Further on, the elevated 
inflammatory markers were consistent with previous results from the CT scans, their lung 
function and the HRQoL (Wilson et al., 1998).  
 
 
1.8 | Pulmonary Sarcoidosis 
 Sarcoidosis as a general disease can affect any parts of the body including the skin, muscles, 
nervous system, nose, sinuses and eyes, the heart, lungs, liver or spleen. Although sarcoidosis 
has not been defined as a lung condition, in approximately 90% of cases the lungs or the 
tracheobronchial lymph glands are affected.  
Pulmonary sarcoidosis is characterised by accumulation of granulomas (cell lumps) in the 
lungs, which in time affects the natural activity of the lungs and body (British Lung Foundation, 
2012). 
 
1.8.1  | Statistics in Pulmonary Sarcoidosis 
 Pulmonary sarcoidosis usually affects individuals with ages between 30 and 60 years old and 
is very rare in children. During 2008-2012 about 108,000 individuals in the UK developed 
pulmonary sarcoidosis. Based on the regional statistical prevalence of people in the UK with 
pulmonary sarcoidosis, between 2004 and 2012, the highest rates were in London, Northern 




or Afro-Caribbean descent that predominantly live in London, Scotland and Ireland (Table 
1.11). 
 
Table 1.11 | Regional variation of people that have developed or lived with pulmonary 
sarcoidosis in the interval of 2008-2012 
The prevailing cases of pulmonary sarcoidosis have been registered in Northern Ireland, 
London and Scotland. The outcomes may rely on the regional variation caused by Irish and 
people of Afro-Caribbean descent that predominantly live in Ireland, London or Scotland 




Pulmonary sarcoidosis indicates similar incidences in both men and women, which rules out 
any differences based on gender.  The mortality rates in pulmonary sarcoidosis indicate a total 
of 170 individuals that died in 2012, which accounts for 0.1% of all deaths from lung disease 





1.8.2 | Causes of Pulmonary Sarcoidosis 
The causes of pulmonary sarcoidosis remain unknown; however, the systemic nature of the 
disease has been indicated due to overproduction of white blood cells (Duchemann et al., 
2016). It is likely that genetic susceptibility is a cause of sarcoidosis as it has been observed in 
monozygotic twins, the medical family history of patients that were currently suffering from 
the disease and the high incidence of the condition amongst specific ethnicities (Spagnolo and 
Schwartz, 2013). However, Spagnolo and Schwartz (2013) also argue that the pathophysiology 
of sarcoidosis may result in fact from a large variety of genetic and environmental factors 
operating simultaneously, each contributing with the precise proportions that can trigger the 
disease. 
Depending on the disease severity, people suffering from acute pulmonary sarcoidosis may 
experience dry coughing, dyspnoea, enlarged tracheobronchial lymph glands, fever, hoarse 
voice or joint pains. Conversely, chronic pulmonary sarcoidosis develops gradually and 
presents fewer symptoms, but it can worsen in time (British Lung Foundation, 2012). 
Giving the fact that pulmonary sarcoidosis shares some symptoms with other respiratory 
diseases such as bronchiectasis and IPF, diagnosis is dependent on a CT scan or chest X-ray or 
an endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) procedure. 
EBUS-TBNA is a sensitive tool for the diagnosis of lung disease not visible with conventional 
bronchoscopy such as pulmonary sarcoidosis.  
 
1.8.3 | Treatment and Management of Pulmonary Sarcoidosis 
 People with acute sarcoidosis usually do not require treatment, although for severe cases, 
steroids are used to improve breathing. Steroids are usually prescribed for a short period of 




regime needs to be strictly followed otherwise the disease may regress and cause more damage. 
People with sarcoidosis are prone to accumulate increased levels of calcium, especially in their 
blood and urine. For this reason, calcium and vitamin D supplements are not recommended for 
individuals suffering from sarcoidosis as they should obtain these from a balanced diet (British 
Lung Foundation, 2012). 
Duchemann et al. (2016) obtained metabolomic profiles of saliva from 24 patients suffering 
from sarcoidosis and 45 healthy controls via proton Nuclear Magnetic Resonance (NMR) 
spectroscopy. The results indicated several altered metabolites in the saliva samples of 
sarcoidosis patients in comparison to the healthy control samples, as well as a dysregulation of 
low levels of methanol and butyrate and high levels of acetate, lactate and N-butyrate. This 
study has confirmed that NMR metabolomics can distinguish specific biomarkers in saliva 
samples of sarcoidosis patients from the healthy individuals, which can be particularly 
beneficial in understanding the aetiology of this respiratory disease. 
 
1.9 | Future Perspectives on Respiratory Diseases 
The burden of respiratory diseases in the UK and worldwide, has proven to affect the economy, 
the healthcare system but most importantly peoples’ lives. Regardless of the efforts that are 
being made in order to deal with this difficult task, mortality rates caused by lung diseases 
continue to increase year by year, leaving the effect of treatment and disease management 
powerless or with a transient effect. 
A challenging problem for clinicians is determining the prognosis and diagnosis of respiratory 
diseases, due to their similarity in symptoms or co-morbidities.  
Biomarkers from easily obtainable biofluids such as sputum, blood and urine have proven to 




diseases and render accurate diagnoses. Additionally, biomarkers offer the opportunity of 
observing the natural disease progression at molecular level, which in turn may provide a better 
understanding of its pathogenesis.  
The utility biomarkers provide is the potential of determining the causes of disease progression 
and provide well-defined ways of disease classification for improved methods of prognosis and 
diagnosis in respiratory diseases.  
 
The research described in this thesis will test if saliva is a reliable biofluid that can discriminate 
between respiratory diseases in comparison with controls through metabolomic and 
microbiomic analyses; and if it can represent a potential biosample for prospective studies with 














CHAPTER 2 | Biomarkers 
The research can directly impact on clinical practice in the identification of biological markers 
(biomarkers) from biological fluids (biofluids).  
Biomarkers have been utilised for diagnostic testing for more than 50 years and have 
established clinical value. Moreover, biomarkers offer the potential of assessing the treatment 
efficacy and aiding the development of new drugs, particularly in the area of therapeutic 
medicine for cancer (Gene-Quantification, 2013). 
Formerly, biomarkers were defined as “cellular, biochemical or molecular alterations that are 
measurable in biological media such as human tissues, cells, or body fluids” (Gene-
Quantification, 2013; Hulka, 1990). Nowadays the definition of biomarkers became more 
specific: “a characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention or other health care intervention” in accordance with the Biomarker Consortium 
of the Foundation for the National Institutes of Health (FNIH) in 2011. Thus, a given biomarker 
should be precise enough to reveal an exact biological characteristic or a measurable alteration 
in an organism, and is linked directly with a physiological condition or disease status. 
Biomarkers are beneficial practically for the entire course of a disease development. Before 
diagnosis, they offer the possibility for screening and risk assessment; during the diagnostic 
process, biomarkers are crucial for determining the stage and grade of the disease for the 
selection of the initial therapy; lastly, during the treatment period, they are helpful for 
monitoring the therapy outcome (Atkinson, 2001). 
Biological markers from biofluids such as sputum, serum, plasma and urine provide early 




prognosis, streamlining drug therapy use, as well as evaluation of the clinical outcomes of 
specific treatments (Gene-Quantification, 2013).  
Formerly, the biomarker identification has involved laborious investigations of defined cells, 
genes, proteins or biochemicals.  
Recently the identification of biomarkers involves multi ‘-omics’ layers or any other 
phenotypic measures regarding an individual’s health status. The use of ‘-omics’ (proteomics, 
metabolomics, microbiomics, genomics, etc.) and other high throughput technologies has 
allowed researchers to rapidly measure many variable and in this way, identify more than in 
the past decades. Therefore, these analytical improvements and high-level technologies using 
the ‘-omics’ expertise, offer the advantage of generating more candidate biomarkers with 
possible clinical value. Coupled to this has been the development of bioinformatical tools 
which are integrate large data sets that derive statistically robust biomarkers linked to such as 
disease pathways and the pharmacologic outcome of medicines.  
Biological markers aid in the understanding of disease progression, which gives them a crucial 
role in helping shape any medical treatment strategies. This in turn, may facilitate in tracking 
a disease from its initial manifestation until the terminal stage and conduct a variety of clinical 
technologies and functions such as molecular diagnostics, drug discovery, clinical trials and 
complex bioinformatical analysis (Gene-Quantification, 2013). 
 
2.1 | Saliva  
In the last century, saliva has emerged as a viable alternative to blood sampling by allowing, 
in certain cases, cost-effective and rapid diagnoses. Notably, saliva, exemplifies an ideal 




be further used for clinical applications in monitoring the health status, the disease onset and 
progression of a patient.  
Saliva is produced and secreted from the three-paired extrinsic salivary glands (Figure 2.1). 
The basic secretary units of salivary glands (acini) secrete a fluid that contains water, 
electrolytes (Wotman et al., 1967; Dawes, 1969), mucus (Watanabe, 1948, Miglani, 
Raghupathy, 1968) and enzymes (Meites, Rogols, 1971; Pigman, Reid, 1952; Raus, Tarbet, 
Miklos, 1968). The fluid then flows out of the acinus into the collecting ducts, where its 
composition is altered. Finally, the small collecting ducts within the salivary glands join into 
larger ducts, which eventually form a single duct that drains into the oral cavity (Schneyer and 
Schneyer, 1964).  
 
 
Figure 2.1 | Representation of the salivary glands 
The two parotid glands represent the largest salivary glands, positioned all around the 
mandibular ramus (in humans) and produce 20% of the total salivary content in the oral cavity. 
The submandibular glands, located beneath the lower jaws, produce approximately 65-70% of 
saliva, despite the fact that they are much smaller than the parotid glands. The sublingual 
glands, situated inferior to the tongue, anterior to the submandibular glands and approximately 





Human saliva consists of 95-99.4% water and various minerals plus electrolytes (such as 
potassium, bicarbonate, sodium, calcium and chloride), mucus, white blood cells, epithelial 
cells, glycoproteins, enzymes and antimicrobial compounds such as Immunoglobulin A (IgA), 
lactoferrin and lysozymes (Farnaud et al., 2010).   
Measurement of total organic constituents in salivary electrolytes, comprise sodium and 
chloride that contain a mmol/L concentration lower than plasma; calcium which has a mmol/L 
concentration similar to plasma; iodine, potassium and bicarbonate with a mmol/L 
concentration higher than plasma, and ultimately magnesium and phosphate (Boron, 2003).  
 
2.2 | Validation of Salivary Biomarkers 
Saliva is very attractive as a source of biomarkers as it can be obtained with minimal anxiety 
and discomfort to the patients and will thereby increase their willingness to undergo health 
inspections (Zhang et al., 2012; Wang et al., 2012; Kumada et al., 2007). The easiness and 
rapid collection of uninduced saliva offers the opportunity of obtaining real-time levels of 
biomarkers, which constitutes an advantage factor in comparison with other biofluids such as 
urine (Soo-Quee Koh and Choon-Huat Koh, 2007). However, previously, the use of human 
saliva as a diagnostic biofluid constituted a barrier, as it was believed that it possessed less 
informative analytes (or at least, in lower concentrations) than present in serum. However, 
Zhang et al. (2013), suggests that whole saliva should be used more frequently for diagnosing 
various human diseases because it is readily collected and even more, contains serum 
constituents as well. Interestingly, Bibby (1949) and Miletich (2010), highlight that since 
ancient times, doctors of traditional Chinese medicine have suggested that saliva and blood 





The number of proof-of-principle assays based on saliva, has increased in the past years, which 
suggest this biofluid is relevant for the monitoring diseases and such as immune responses to 
viral infections or detection of illicit drug use (Zhang et al., 2013; Wu et al., 2011; Nagler et 
al., 2007). This has offered the possibility to discover a large number of medically valuable 
analytes, which assist in the identification of saliva biomarkers for different diseases including 
cancer, autoimmune diseases, viral and bacterial diseases, cardiovascular diseases and HIV 
(Epstein et al., 2000). In addition, approximatively 20% of the total salivary proteins were also 
identified in plasma, both fluids indicating disease-linkage and comparable functional diversity 
in their proteins (Bandhakavi et al., 2009). 
 
 A research study reviewed by Zhang et al. (2009) that compared saliva, blood and urine, 
concluded the fact that the diagnostic power of saliva can be comparable with that of blood, as 
it harbours approximately 30% of the same proteins found in blood. Similarly, Perez-Cornejo 
et al. (2012), assert that saliva is as beneficial for clinical applications as blood and urine and 
even more, it is easier to process it during laboratory procedures because it does not clot, like 
blood. Moreover, in their later study Zhang et al. (2013), confirms that saliva is indeed 
recognised as an effective diagnostic medium for detection of disease biomarkers through the 
application of proteomic analyses.  
Following on from such work, salivary diagnostic approaches have only been recently 
developed and assessed to provide scientifically plausible, cost-effective, non- invasive and 
convenient detection methods for clinical applications. Thus, salivary biomarkers have proven 
to be extremely efficient in monitoring and predicting other medical conditions as cognitive 
impairment and Alzheimer’s disease (Liang et al., 2016) or occupational stress (Soo-Quee Koh 
and Choon-Huat Koh, 2007). When examining the influence of stress in occupational health 




and Choon-Huat Koh (2007) have indicated a correlation between stress and increased levels 
of certain salivary biomarkers. The increased levels of salivary biomarkers caused by chronic 
or acute stress were cortisol, immunoglobulin A (IgA), lysozyme, salivary -amylase and 
lastly, chromogranin A. Interestingly, smokers showed higher levels of stress biomarkers, 
compared to the non-smokers. Suzuki et al. (2016) had similar findings in a research based on 
the biomarker levels of salivary stress in cigarette smoking young adults. Results from profiled 
saliva samples indicated increased concentrations of cortisol, secretory immunoglobulin A 
(SIgA), interleukin-1 (IL-1) and TNF- in association with mood states of tension-anxiety, 
depression, hostility, fatigue and confusion. Saliva also holds a potential intrinsic value for 
detecting proliferation disorders, such as cancer (Coller, 2014). Moreover, Iorgulescu (2009) 
reveals that changes in saliva represent an indicative of the wellness of the patient. 
 
2.3 Biomarkers in Saliva for Pulmonary Diseases  
Many lung diseases can cause changes in certain chemicals in individuals' saliva, sputum, blood 
and urine. If such biomarkers are detectable sooner or easily, before a patient develops any 
specific symptoms it impacts on the treatment of pulmonary diseases (Lin et al., 2013).  
At present, it is known that sputum samples originate from the central respiratory airways and 
its microbiological components (e.g. viruses, bacteria), cellular components (e.g. eosinophils, 
neutrophils) and protein components (e.g. mucins, cytokines) (Nicholas and Djukanovic, 
2009). Hence, sputum is recognised as an efficient candidate for monitoring and assessing lung 
diseases.  
There is a pressing need to discover non-invasive new techniques of detecting lung cancer in 
its early stage. For this reason, early detection represents one of the most feasible and promising 




in the field of salivary biomarkers, show valid outcomes designed for the analysis of lung 
cancer transcriptomes (Zhang et al., 2012a). Based on the logistic regression model that 
combined five messenger ribonucleic acid (mRNA) biomarkers, salivary transcriptomes of 
lung cancer patients were compared to the normal control patients. Results showed 93.75% 
sensitivity and 82.81% specificity in the pre-validation sample set with a calculation of the area 
under the curve (AUC) value of 0.93 (Zhang et al., 2012). This in fact, proves that the salivary 
mRNA biomarkers carry the potential for detecting lung cancer. Additionally, following Xiao 
et al. (2012), when profiling proteins in saliva, potential biomarkers were revealed, indicative 
of cancerous cells. Thus, the candidate biomarkers in lung cancer patients compared to the 
healthy control subjects, displayed in the pre-validation sample set 88.5% sensitivity and 92.3% 
specificity with AUC =0.90 (Xiao et al., 2012).  
In consequence, these results suggest that a simple saliva test may be proficient enough for the 
screening and detection of various diseases, but most importantly it may be applied for serious 
lung diseases, such as lung cancer with the aim of detecting it early and increasing the five-
year survival rate of individuals. This in turn, can be used extensively for future medical 
diagnostics. 
Following the work of Lee and Wong (2009), saliva is recognised as containing 
microorganisms found in the mouth and sputum contains microorganisms found in the lungs. 
Such microbiological, cellular and protein components found in sputum can be used as markers 
of disease severity, exacerbation, susceptibility or progression. These can offer specific 
information regarding the patient’s inflammatory cell content as well as physiological 
properties of sputum, such as purulence and bacterial load. Similar assessments have not been 




The main challenge of this project is to validate the hypothesis that saliva can differentiate 
between pulmonary diseases through metabolomics and microbiomic assessments. 
Subsequently, when linked to other more in-depth research, the results of these studies will 
constitute in a large body of knowledge displaying characteristics in both healthy subjects and 








CHAPTER 3 | Assessment of the Human Salivary Metabolome in Pulmonary Diseases 
 
3.1 | Introduction 
Metabolomics is one of the new “omic” sciences and a metabolomic study represents the 
evaluation of endogenous small-molecules called metabolites within a biological sample.   
Metabolomics analyses have become a pivotal platform for their potential of discovering 
clinically relevant biomarkers within a biological system, that are simultaneously affected by 
a disease (Zhang et al., 2012b). Metabolomics utilizes two principal technological methods: 
mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy. Both MS and 
NMR can be used for metabolomics fingerprinting and profiling, according to their extent of 
applicability, each with their own advantages and limitations (Madsen, Lundstedt and Trygg, 
2010; Emwas, 2015). Additionally, NMR spectroscopy is a quantitative method, which does 
not necessitate the additional separation and derivatization steps for the sample preparation as 
in MS, although it is limited in sensitivity. Mass spectrometry, on the other hand, provides an 
excellent analysis approach for metabolomics research because it combines a sensitivity and 
selectivity platform, as well as different ionization techniques and mass analyser technology, 
which in turn increases the detectability of metabolites (Emwas, 2015).  
The human metabolome comprises all of the metabolites in the body which are vital 
physiological and pathological indicators of the state of a biological system. Additionally, the 
metabolite profiles constitute unique chemical “fingerprints” that can provide insights with 
respect to a disease’s cause, state and progression, through the identification and assessment of 





The Human Metabolome Project is an attempt to unify metabolomics approaches that followed 
similar methodologies starting from the sample preparation and carried out until the final 
biological interpretations (Madsen, Lundstedt and Trygg, 2010). According to Zhang et al. 
(2012d), in order to acquire an accurate representation of the human metabolome or any other 
biological system, the use of two or more MS techniques may render better results. At the 
moment, there are no methodological approaches able to analyse the complexity of metabolites 
within the whole human metabolome. The mass spectrometry technological methods in 
metabolomics will indicate metabolites based on their mass-to-charge ratio (m/z) in charged 
particles of a biofluid (Spratlin, Serkova and Eckhardt, 2009).  
A mass spectrometry technique, also employed in this study is the flow infusion electrospray 
mass spectrometry (FIE-MS). This method addresses several issues that are usually 
problematic when achieving adequate metabolome coverage due to the deficiency regarding 
the instrument dynamic range, mass resolution, degree of sensitivity and signal identification 
(Draper et al., 2013). In the context of FIE-MS, sputum metabolite changes with an AUC 
greater than 0.8 were identified only in lung cancer patients when compared to healthy controls 
(Cameron et al., 2016). A recent study in the field (O’Shea et al., 2016), based on profiled 
sputum samples from patients with NSCLC and SCLC and age-matched smoking controls 
utilizing FIE-MS, has indicated an 80% sensitivity and 100% specificity for predicting SCLC. 
Furthermore, the metabolomics profiling identified six candidate biomarkers, which have 
already been associated with lung cancer. For instance, the enzyme glycine decarboxylase 
(GLDC), which is responsible for the degradation of glycine has been linked to NSCLC due to 
increased levels of GLDC and very low degree of glycine found in individuals suffering from 
non-small cell lung carcinoma (Zhang et al., 2012e).  
These examples alone highlight the potential of FIE-MS metabolic profiling of biofluids and 




for lung cancer. Additionally, flow infusion electrospray mass spectrometry may be an 
essential contributor in the whole process of metabolite detection for improved clinical 
diagnostic pathways in patients with lung cancer and other pulmonary conditions. 
Although the metabolomics techniques of analysis generally produce considerable amounts of 
data, for experiments focused on understanding the disease dynamics within a human 
metabolome, only certain parts of the whole metabolome may exhibit alterations. A study based 
on MS that involved the profiled saliva samples from 215 patients suffering of breast, oral and 
pancreatic cancers, managed to identify no more than 57 metabolites related to specific 
alterations linked to either of the three cancers (Sugimoto et al., 2010).  
Despite some significant advancements that have been made with the contribution of 
metabolomics in the field of cancer, unfortunately these cover only a few that focus on the lung 
cancer. However, this is not the case for all respiratory diseases to impose the same difficulty, 
since COPD is being particularly studied. Indeed, metabolites changes that are representative 
for all COPD GOLD severity stages have been defined (Ubhi et al., 2012).  
 
  3.1.1 | Objectives 
Generally, saliva is one of the least studied biofluid in lung cancer metabolomics. However, 
the potential of saliva as a biomarker for other respiratory diseases has started to receive more 
attention in the past decades. This is due to the complexity of its constituents’ non-invasiveness 
method of collection, and most importantly direct link to the respiratory tract. 
Provided that saliva depicts specific symptoms of the inflammatory lung airways, this can be 
further employed in metabolomics profiling techniques. This may offer better insights 





The main aim presented in this segment of study was to explore the salivary metabolome from 
eight patients with confirmed lung cancer and 47 COPD patients contrasted with 37 “healthy” 
controls. This was done in order to demonstrate that saliva as a biofluid, allows discrimination 
between pulmonary diseases when employed in metabolomics analyses. To this, 16 patients 
suffering of asthma, three from pneumonia, one of bronchiectasis, two of IPF and three of 
sarcoidosis were added to the analysis to increase the database and add a greater variety to it. 
Moreover, the study investigations of all 117 processed saliva samples were carried out with 
the aid of the MetaboAnalyst 3.0 (Xia et al., 2015) analysis platform on diverse grouping 
variables such as diagnosis, disease severity and stage (i.e. GOLD stage), age group, gender, 
hospitals, smoking status, medical history and other symptoms. 
 
 
   3.2 | Materials and Methods  
 
  3.2.1 | Patient Recruitment and Saliva Sampling  
This study was carried in conjunction with the Hywel Dda University Health Board with the 
ethical approval (16/WA/0036) from the loco-regional ethical committee and can be also 
accessed on the International Standard Randomised Controlled Trials Number (ISRCTN) 
registry under the study number ISRCTN16657101. All samples and data were anonymised 
prior to being processed and analysed. Moreover, this clinical study of saliva constitutes a 
division from the project “Novel Technologies for Detecting and Monitoring Pulmonary 
Diseases” based on other biofluids as sputum, blood (plasma and serum) and urine. 
Patient recruitment took place between the time intervals of February 2016 to August 2016 




uninduced saliva samples employed in this research study were collected from patients 
suffering from pulmonary diseases from three different hospital sites around Wales: Bronglais 
Hospital (BGH) from Aberystwyth, Glangwili Hospital (GGH) from Carmarthen and Prince 
Philip Hospital (PPH) from Llanelli with the help of research nurses and consultant doctors. 
The first crucial step regarding patient recruitment, involved obtaining the patients’ signed 
informed consent in duplicate so that one copy can be given to the consented person and the 
other to be attached in the patient’s medical history file. The recruitment protocol consisted in 
a Participant Information Sheet (Appendix Chapter 3, Supplementary Figure 3.1), which was 
self-explanatory and contained information and frequently asked questions about the study, for 
the patient’s better acknowledgement. Following, the Clinical Information Datasheet, which 
was designed as a questionnaire format with the aim of recording as much as possible 
information regarding the patient’s medical status and diagnosis, age, gender, specific 
symptoms, disease severity (FEV1/FVC for GOLD staging in COPD), 
medication/antimicrobial medication and past medical history/family medical history.  
Every piece of information that was recorded constituted an important variable in the analysis 
and interpretation processes. Finally, the samples of saliva collected were transported and 
stored accordingly at -80°C in the research laboratories at the Institute of Biological, 
Environmental and Rural Sciences (IBERS) of Aberystwyth University.  
Before analysing the data, all saliva samples have been classified into four groups based on 
patient diagnosis: LC, COPD (comprising emphysema and chronic bronchitis), “Other” 
category (including asthma, pneumonia, idiopathic pulmonary fibrosis, bronchiectasis and 






3.2.3 | Processing of Raw Saliva 
 The protocol was adapted from that of Cameron et al. (2016). In order to wash the glass beads 
(Sigma-Aldrich, Dorset, UK), 200 mg of glass beads powder were washed in 2 ml acetone and 
placed on a vortex mixer (Vortex-Genie 2 Shaker) at the full speed of 2700 rpm for 30 seconds. 
Further on, the microcentrifuge tubes with the weighted 200 mg glass beads were centrifugated 
(Heraeus Multifuge 3SR) at 1800 x g for one minute and left uncapped in the fume cupboard 
overnight to dry out completely. 
 
For the sample preparation, saliva samples were thawed on ice at 4˚C and 50 µl of the 
supernatant were individually transferred to a sterile 2 ml microcentrifuge tube to which 7.5 
mg of  ≤160 µM (particle size) acetone-washed glass beads were added. 
To these, 380 µl of a solvent mix of high performance liquid chromatography (HPLC) grade 
methanol (MeOH) and chloroform (CHCl3), in a ratio of 4:1 were added in order to dissolve 
the solute (saliva) and also to separate and isolate the polar from non-polar metabolites in the 
biological samples and stop the intracellular metabolism. For a better accuracy and consistency, 
the HPLC mix was prepared in a large quantity of approximatively 100 ml and stored at room 
temperature in a Duran bottle, so that all 117 saliva samples were treated with the same solvent. 
The HPLC grade mix represents a helpful step in metabolic fingerprinting, as it acts as an 
extracting agent by making the cell envelope permeable and thus, triggering the release of 
intracellular metabolites from the saliva samples (The Metabolomics Lab, 2014). 
To homogenise the mixture and disrupt the cells, saliva samples were placed on a vortex mixer 
for five seconds. Following this, samples were shaken for 20 minutes at room temperature and 
then stored at -20˚C for 20 minutes to allow precipitation. Samples then underwent 




minutes at 4˚C. Following this the supernatant was transferred to a sterile 2 ml microcentrifuge 
tube.  
From this, 100 µl were transferred to a MS vial and capped. For a better accuracy and quality 
control validation, a vial with 100 µl of the gene pool (composed of a mixture of 1 µl of each 
sample used in the experiment) and a vial only with the HPLC mix were added to the analysis 
of the MS instrument too. In order to preserve the saliva samples and prevent bacterial growth, 
samples were stored at -20˚C until run, in a randomised order using an auto-sampler.  
The following final steps were performed with the help of Dr Manfred Beckham – Aberystwyth 
University. Subsequently, for each sample, 20 µl were injected into a flow volume of 60 µl per 
minute water-methanol, in a ratio of 70% water and 30% methanol, using a Surveyor flow 
infusion electrospray mass spectrometry for high throughput, non-targeted metabolite 
fingerprinting (FIE-MS) (Thermo Scientific, MA, USA). Data acquisition for each saliva 
sample was done by alternating the positive and negative ionisation modes, throughout four 
different scan ranges (15-110 m/z, 100-220 m/z, 210-510 m/z, 500-1200 m/z) (Draper et al., 
2013; Cameron, 2015), on an LTQ linear ion trap with an acquisition time of five minutes 
(Thermo Electron Corporation, CA, USA). 
 
3.2.4 | Data Analysis  
Following, raw data outputs from the MS instrument (FIE-MS fingerprinting) were converted 
into an open file format. Data normalisation consisted of Total Ion Current (TIC) normalisation, 
according to the following equation: TIC normalised data =[data/ sum(data) ÷ median(data)] 
as shown in Figure 3.1 (a, b and c).  
Then, centroided intensity peaks were derived from their base64 elements for all m/z values 




from lowest to highest and referenced back to their relevant identities and labels using the 
metadata spreadsheet.  
Finally, data was base-10 log transformed and the normalised abundances were subsequently 
analysed using the MetaboAnalyst 3.0 platform (Xia et al., 2015) as displayed in Figure 3.1 (d, 
e and f). Following, the unpaired samples with their corresponding diagnoses were arranged in 
rows and the features were arranged in columns [peaks (mz/retention time(rt))]. The uploaded 
file was in comma separated values (.csv) format with numeric values only exported from the 
Microsoft© Excel™ 2013 spreadsheet.  
In order to minimise variance and preserve the integrity of metabolites, the key elements for 
data integrity check, outlier detection, quality control, normalisation and scaling, were kept as 
similar as possible for each completed analysis. The purpose of this approach was to make the 
technical replicate groups (saliva samples) comparable with each other, yet without introducing 
too much variation between them. The profiling method used was the non-targeted 







Figure 3.1 | Data analysis flowchart following flow infusion electrospray mass spectrometric 
analysis of saliva profiles 
(A) Select optimal quantifier ions by centroid intensity peaks derived from their base64 elements 
for all m/z values above 55.0. (B) Sort peak areas lowest to highest and export these back to their 
relevant identities and labels in order to receive a data matrix (metadata). Data was binned below 
0.25 and mean centred. (C) Normalise and transform data by Total Ion Current (TIC): TIC 
normalised data =[data/ sum (data) ÷ median (data)]. (D) Structure data according to background 
information regarding each sample and diagnosis class. (E) Obtain significant and unknown data 
structures by univariate and multivariate statistics. (F) Interpret findings, verify the hypotheses or 
generate new ones. 
 
For the data filtering, which aims spectral alignment or binning, the interquartile range (IQR) 
analysis was chosen. The purpose of the IQR is to remove the outliers (highest and lowest 






Subsequently, data normalisation, which allows general–purpose adjustment for differences 
among samples was applied to all analyses to convert them to a normal distribution. The 
rationale of choosing these settings was to preserve the metadata in its initial format as much 
as possible, thus introduce less systematic variation and improve the performance of 
downstream statistical analysis, so the outcome would be as accurate as possible, displayed in 




 Figure 3.2 | Data Normalization of the COPD, LC, Other and HC classes 
 Normalisation of data comprised of four groups containing COPD, LC, Other and HC 
using the interquartile range (IQR) data filter. Sample normalization was employed for all 
analyses, as shown here for the first investigation of the four classes including LC, COPD 
(comprising emphysema and chronic bronchitis), Other (asthma, pneumonia, IPF, 




3.3 | Results 
 
  3.3.1 | Metabolomics Analyses of LC, COPD, Other and HC 
The initial analysis performed with the MetaboAnalyst 3.0 platform was conducted on a data 
matrix of 117 samples each with 3771 peaks (mz/rt). These comprised four groups: LC, COPD, 
“Other” group including other pulmonary diseases e.g.: asthma, sarcoidosis, idiopathic 
pulmonary fibrosis (IPF) and bronchiectasis, and healthy controls (HCs) including never-, ex-
, non- or current-smokers.  
 
 The initial assessments tested whether there were any differences between the three classes of 
respiratory diseases (COPD, LC and Other) in comparison with the HC. In this way, any 
significant patterns could be determined with the use of one-way analysis of variance 
(ANOVA) or t-tests and chemometric multivariate analyses as the principal component 
analysis (PCA) and partial least squares-discriminant analysis (PLS-DA) or heatmaps.  
Supplementary information regarding participant diagnosis, age group, smoking status and 
FEV1% predicted, are detailed in Chapter 3 Appendix, Supplementary Table 3.1, Table 3.2, 




As shown in Figure 3.3 the ANOVA test differentiated between the samples analysed with the 
cut-off threshold scores of approximately higher than 1.4 and the significance plot of the P 
value threshold 0.05.  
The second ANOVA test was performed with a new matrix that excluded the Other diseases 
class of samples. This was done as this represented a highly variable group. In this case, the 
analysis was focused more on the classes with patients that had only one diagnosis per group 
(COPD, LC and HC) and showed significance above the threshold. 
Principal Component Analysis was employed to visualise difference between the groups 
(Figure 3.4); one which included the “Other” category and another where this was excluded.  
 
Only when the “Other” category was excluded was partial separation of the COPD, LC and 
HC evident. Interestingly, two outliers, which are indicated by the blue arrows in Figure 3.4, 
have been plotted out of their clusters in the PCA carried only on the three classes (COPD, LC, 
HC), where the same observed in the first PCA conducted on the four classes (COPD, LC,  
 
Figure 3.3 | ANOVA analysis of saliva samples from four different groups COPD, LC 
Other and HC 
The post-hoc significance comparison column from the left-hand side, provided a 
preliminary overview regarding features that were automatically selected with the cut-off 
threshold, approximately higher than 1.4.  The right-hand side however, displayed only the 
important features of the three classes of COPD, LC and HC significant in discriminating 






The HC outlier is represented by sample A122, which was noted as a female current smoker 
belonging to the 40s-age group recruited during a General Respiratory Clinic. The outlier of 
this sample was closely positioned to an A067 COPD saliva sample, represented by a female 
ex-smoker belonging to the 50s age group with a value of 28 pack years and suspected 
infection. One reason that may have caused these two saliva samples to be plotted out of the 
cluster might have been influenced by common variables as smoking and medical history 
including hypertension (HTN) and probability of a respiratory infection. Furthermore, an 
unusual overlapping is displayed between the LC and HC groups, and partially with the COPD 
group. Otherwise, the PCA carried on the three classes showed there is evident metabolite 
 
 
Figure 3.4 | Principal component analyses of COPD, LC, Other and HC 
Principal component analysis between the matrix containing all four classes of diagnoses LC, COPD, 
Other and HC and the matrix composed of the significant values post ANOVA test, containing the COPD, 
LC and HC classes only. As expected, by removing the Other diagnoses classes and using only the 
significant samples selected by the ANOVA test, the second PCA (Component 2) seems to discriminate 
better between the three classes of COPD, LC and HC. The outliers (indicated by blue arrows) have 





variation between COPD patients in comparison with LC and HC patients. The LC and HC 
classes overlap (as displayed below in the following analyses as well) due to a possible 
similarity in metabolites. 
Partial least squares-discriminant analysis was performed with the original PCA summarized 
variables (Figure 3.5). This produced better separation that in Figure 3.4. Similarly to the PCA, 
sample A122 represented an outlier once again as it correlated more with the COPD class. A 
new sample that constituted an outlier was a HC identified as A135 ex-smoker male belonging 
to the 80s age group with a total of 15 pack years and showing common symptoms of dyspnoea 





Figure 3.5 | PLS-DA performed on the three classes of COPD, LC and HC  
The HC outlier (indicated by blue arrow) from the HC group presented a smoking history of 




Subsequently, a Random Forest Plot (Figure 3.6) was used to represent the mean decrease 
accuracy values (VIP scores) of relevant metabolites identified in the four classes.  
 
 
Metabolites that are either higher or lower in all four classes are of main interest, because they 
reveal biochemical thresholds that can aid in understanding on what occurs at a molecular level 
during inflammation. This in turn can offer a greater insight with regards to exacerbation crises 
in COPD patients. As displayed in Figure 3.6, all metabolites were elevated in the COPD class, 
suggesting a high risk of exacerbations as it was also confirmed in the case of several patients. 
Healthy Control and LC patient samples displayed a combination of medium to lower levels in 
Figure 3.6 | Random Forest Plot displaying the VIP scores of relevant metabolites 
identified by MetaboAnalyst 3.0 in the four classes of COPD, HC, LC and Other 
Detected values represent metabolites which have potential in terms of diagnostic markers 
and inflammation. As shown in the colour key: red signifies high or upregulated, yellow – 
medium and green shows low or downregulated, according to the VIP scores of a certain 
metabolite (vertical values on the left hand-side). Therefore, all identified metabolites here 
are upregulated in COPD samples, medium to downregulated in HC and LC, and 




metabolites, however the Other group has shown all decreased levels. A more in depth study 
should be allocated to the Other class with more data, in order to justify the low levels of these 
metabolites.  
For a better perception of how saliva samples from patients with COPD, LC and Other 
diagnoses are related between each other and in comparison with the healthy individuals, every 
class of diagnoses has been analysed in tandem. 
 
3.3.2 | Metabolomics Analysis of COPD and HC 
Data analysis was carried exactly as in the previous subsection 3.3.1. The difference in the 
type of analysis was given by the fact that the group was restricted to two classes only, 
therefore, instead of ANOVA, a t-test analysis was performed. Fifty relevant variables were 
selected after the threshold cut-off and the P-values were transformed by –log10 so that more 





Figure 3.7 | PCA (A) and PLS-DA (B) of the COPD and HC classes with selected significant 
variables indicated after the t-test analysis 
PCA and PLS-DA conducted on the HC and COPD classes revealed two outliers (indicated by blue 
arrows) from each group, which seem to show a repetitive separation when comparted to previous 
analyses.  
 
The PCA has indicated one outlier which did not seem to be integrated in the cluster. This was 
represented by sample A067 from the COPD class, as in the previous analysis from subsection 
3.3.1. Another interesting outlier was sample A135 from the HC class which seemed to indicate 
a trend as it was always in the COPD cluster. The PLS-DA showed a better separation of the 
COPD and HC classes, although an outlier has been identified in this analysis as well. Similar 





3.3.3 | Metabolomics Analysis of COPD and LC 
The PCA and PLS-DA analyses between the COPD and LC classes (see previous subsection 
3.3.1 for data analysis) were similar in partial cluster distribution, even for the outlier sample 
of the COPD class A067 as shown below in Figure 3.8. 
 
Figure 3.8 | Principal Component Analysis and PLS-DA between COPD and LC 
Analyses between the COPD and LC classes performed with the significant values indicated by 
the t-test. PCA analysis is indicated in the A figure and the PLS-DA is indicated in the B figure. 
Both analyses have been distributed in concordance with Component 2 of the graph. Outliers 
are indicated by blue arrows. 
 
 
3.3.4 | Metabolomics Analysis of COPD and Other 
The analyses performed between the COPD and the Other diagnoses groups indicated 
similarity in both the PCA and PLS-DA tests (for data analysis see subsection 3.3.1) with 
only partial separation present. The PCA has shown an outlier from the COPD class 
represented by sample C017 male ex-smoker belonging to the 70s age group. This patient 




important role on the quality of saliva and thus, influence the value of the sample and further, 
the variable as well (Figure 3.9). 
 
 
Moreover, both the PCA and PLS-DA recorded two new candidate samples as outliers which 
belonged to the Other diagnoses group and interfered in the COPD class. Sample A111 was 
represented by a non-smoker male from the 40s age group that was suffering of asthma. 
The second outlier was represented by sample A108 which was an ex-smoker male belonging 
to the 60s age group which was suffering of asthma (often asthma exacerbations) and FEV1%  
of 54 (GOLD 2 or Moderate stage) and a total of 45 pack years.  
 
Figure 3.9 | Scores plots of PCA (A) and PLS-DA (B) tests performed between the COPD and 
Other diagnoses groups  
Both types of analyses presented similar clustering with outliers represented by samples from patients 




These results suggest that outliers are indeed represented by the quality of the saliva samples, 
which in turn can reveal some similarity in symptoms of acute stages of respiratory diseases as 
COPD and asthma (Figure 3.9). 
 
    3.3.5 | Metabolomics Analysis of LC and HC 
Data analyses of the matrix were done as described in subsection 3.3.1. The PCA test 
indicated less clustering between the two classes of HC and LC compared to the supervised 
PLS-DA. Additionally, the PCA result may have been influenced by certain outliers 
represented by the COPD class. Also, the separation between clusters on the PCA test, 
occurred mostly along Component 1 (Figure 3.10).  
 
 
Figure 3.10 | PCA (A) and PLS-DA (B) tests between the HC and LC classes 
Separation between clusters in the PCA test occurred mostly along the Component 1 with a few outliers, 






Sample A122 discussed previously in subsection 3.3.1 continued to be a trend as an outlier of 
the HC class.  
Another interesting outlier was represented by the HC sample A059 which was part of the LC 
cluster in the PCA test. Even if it was a HC, sample A059 was represented by a male current 
smoker with an 80 pack years and suspected respiratory infection.  




3.3.6 | Metabolomics Analysis of LC and Other 
The PCA test showed an excellent separation between the LC and Other classes. Therefore, the 
supervised technique of the PLS-DA test was almost unnecessary (data analysis performed as 
mentioned in subsection 3.3.1). Both PCA and PLS-DA tests indicated obvious differences  
between LC and Other classes. One of the detected outliers was the Other samples A111 
discussed previously in subsection 3.3.4. The second outlier belonged to the Other class as 
well, and it was represented by sample C006 which was a female ex-smoker belonging of the 














3.3.7 | Metabolomics Analysis of HC and Other 
Data analysis was performed as described in subsection 3.3.1. Both the unsupervised PCA and 
supervised PLS-DA tests displayed similar clustering with partial separation and a few outliers 
represented by the HC samples A135 and A122 and the Other group samples A111 and A108 




Figure 3.11 | Tests of PCA (A) and PLS-DA (B) between the LC and Other classes 
Both analyses show an evident cluster separation with a few outliers belonging to the Other group. The 
two outliers (indicated by arrows) from the Other class include patients with a history of heavy smoking 






3.3.8 | Metabolomics Analysis of Hospitals and Age Groups 
PCA test between the three hospital sites BGH, GGH and PPH did not show variation in the 
analysis (Figure 3.13) suggesting that any different sampling approaches in each hospital did 
not affect our metabolomic analyses. The outlier indicated by the GGH class is sample C017 
which is represented by an ex-smoker male suffering from COPD from the 70’s age group that 
admitted himself to the hospital due to an exacerbation. The metabolites detected in his samples 
are displaying this fact through separation from its class. 
 
All individuals that participated in this study have been allocated to a specific age group 
depending on their age. Therefore, the range of age groups started from 20s with 24 years old 
Figure 3.12 | Unsupervised PCA (A) and supervised PLS-DA (B) tests indicating the variable 
differences in clusters between the HC and Other diagnoses classes 
The poor variation between the two classes may result due to the fact that the majority of the Other group of 
respiratory diseases included patients suffering of asthma only. These patients are normally stable, only using 
their inhalers occasionally. Therefore, their metabolites may result in being quite similar to those patients 





as the youngest participant and finalising with the 80s with 87 years old as the oldest individual 
that participated. The age group classes did not show much cluster variation as it can be 
observed in Figure 3.13. Additionally, these results indicated that age does not necessarily 
overcome the disease severity, although, most patients recruited were in between 50 and 70 
years old. As most studies based on respiratory diseases tend to employ elder individuals in 
their expertise, it is relevant to acknowledge that a more data may have given different results 




Figure 3.13 | PCA test of the three hospitals and age groups 
Hospitals where the patients have been recruited and saliva samples were collected: Bronglais Hospital in 
Aberystwyth, Glangwili Hospital in Carmarthen and Prince Philip Hospital in Llanelli (A). The age group 





3.3.9 | Metabolomics Analysis of COPD Severity and Gender 
The PCA test based on the severity of COPD GOLD stages (previously explained in subchapter 
1.2, subsection 1.2.6) indicated an accurate representation of the clusters of moderate (MO), 
severe (SE) and very severe (VS). The outlier of the moderate class that was located in the 
severe cluster was represented by sample A101 (arrowed), was a non-smoker female of the 70s 
age group, with an FEV1% Predicted of 66 and a medical history of asthma, acute bronchitis 
and pulmonary embolism. 
 
 
As for the COPD gender, there is an evident difference between the two groups of males and 
females. Clear separation between the clusters occurred mostly along Component 1 as indicated 
above in Figure 3.14. 
 
Figure 3.14 | Representation of the PCA tests of COPD severity and COPD gender 
The COPD severity included moderate (MO), severe (SE) and very severe (VS) based on the 
FEV1% Predicted values (A). The second PCA test was performed based on the COPD gender 




3.3.10 | Metabolomics Analysis of Gender and Smoking Statuses 
The PCA test carried out on current or ex-smokers in males and females from all four classes 
of COPD, LC, Other and HC (Figure 3.15A) showed a poor separation between the clusters. 
The outlier observed in Figure 3.15A is represented by sample C017 which was previously 




As for the PCA test regarding the smoking status, samples were analysed based on the Never, 
Ex-smoker and Current smoker grouping system. The cluster containing samples from 
 
Figure 3.15 | Principal Component Analysis evaluations of the gender and smoking status of the four classes 
COPD, LC, Other and HC 
Analysis of the current and ex-smokers did not show an effective separation between males and females (A). 
Although, the smoking status displayed a better clustering separation specifically with respect to the non-smokers 




individuals that have never smoked showed a better separation, compared to the individuals 
that used to smoke or were still smoking at the time of the samples recruitment (Figure 3.15B).  
The outlier detected in this case, was a sample previously discussed belonging to an ex-smoker 
(A067 mentioned previously in subsection 3.3.3).  
 
 
3.4 | Discussion  
The utilisation of flow infusion electrospray mass spectrometry for metabolomics 
fingerprinting employed to demonstrate if saliva allows discrimination between certain 
respiratory diseases and healthy controls has proved to be successful.  
In this segment of work, three different classes of respiratory diseases including COPD, lung 
cancer, and a general group comprised of asthma, pneumonia, idiopathic pulmonary fibrosis, 
bronchiectasis and sarcoidosis, were compared between each other and to a group of healthy 
controls (never smoked, ex- and current smoker).  
 
All PCA and PLS-DA have been generated by the analysis platform MetaboAnalyst 3.0. For 
all analyses data filtering, editing and normalization were performed identically, specifically 
to avoid introducing more variation in the four classes. In order to obtain accurate results, every 
analysis of the four classes was performed on the significant variables indicated by ANOVA 
or t-tests (depending on the number of variable grouping) with the significance plot of the P-




Additionally, saliva metabolites from patients suffering from pulmonary diseases as COPD or 
lung cancer when compared to healthy controls, showed distinct separation and a good linear 
combination of the variables, as indicated in Figures 3.4 and 3.5.  
 
3.4.1 | Discussion of COPD Microbiome in Comparison with LC, HC and Other 
The class comprising COPD patients differentiated from LC, HC and Other classes in terms of 
metabolites, particularly in the supervised (PLS-DA) analyses and partial cluster separations 
in the unsupervised (PCA) ones. More importantly, the COPD class is the only one that 
contained the majority of patients post or currently on antibiotic medication for suspected or 
confirmed chest infections, low FEV1% values and worrying breathlessness scores on their 
CAT or mMRC tests.   
 
3.4.2 | Discussion of LC Microbiome in Comparison with COPD, HC and Other 
The LC group revealed an interesting result when compared to the HC one, in the PCA 
particularly. The two groups overlapped and similarly to the other analyses, LC and HC always 
showed consistency regarding the grouping linearity. On the other hand, the PLS-DA between 
LC and HC, has shown a relevant separation, similarly to the analysis between LC and Other 
class.  
It was expected for the LC class to cluster nearby the COPD or Other groups, as there was a 
better probability for these three classes to share similar metabolites, since their variables 
(Supplementary Tables 3.5, 3.6 and 3.7) coincided more. However, in relation to these results 
specifically, two different studies based on serum, compared COPD smokers to healthy 
smokers (Chen et al., 2015) and lung cancer to COPD patients (Deja et al., 2014). In addition, 




in 95% sera of all study participants. These 23 metabolic markers were found to be 
differentially-expressed in the group of COPD smokers than in the healthy smokers. Similarly, 
Deja et al. (2014) conducted an expertise based on serum samples collected from 22 COPD 
and 77 lung cancer patients. By running NMR metabolic fingerprint analyses, data was then 
modelled using discriminant orthogonal partial least squares regression (OPLS-DA). The 
OPLS-DA analysis identified a number of putative biomarkers which ascertains that it is 
possible to successfully discriminate between COPD and lung cancer diagnoses (AUC training 
=0.972, AUC test =0.993). The two studies alone correlated with the results obtained in this 
part of work, establishing that COPD and lung cancer can be distinguished based on 
metabolomics biomarkers. 
 
3.4.3 | Discussion of Hospitals and Age Group Analyses 
As expected, in the analysis based on hospital sites there was no difference. All hospital classes 
overlapped since the diagnoses were identical. Patients almost matched between each other 
with regards to the study variables and disease stages. The only different feature was the 
geographical position. The several outliers remarked in this analysis may reflect the differences 
in sampling techniques and sample storage by the research nurses and research students. 
In the age group analysis the separation was not evident between the age classes, although the 
prevailing number of patients was of those belonging to the 50s, 60s or 70s groups. However, 
a repeated analysis with more data for all groups may display different results. Moreover, as 
stated in the clinical literature and specified above in Chapter 1, the majority of pulmonary 





3.4.4 | Discussion of COPD Severity and COPD Gender Analyses 
The metabolomics analysis based on the COPD severity and COPD gender classes have shown 
the greatest degree of separations. The grouping of the COPD severity class was done based 
on the FEV1% values obtained from every patients’ Spirometry test results. These were 
moderate (MO), Severe (SE) and very severe (VS). The classification of the COPD severity 
was done accordingly, thus it matched both the old COPD staging as well as the new GOLD 
grouping (subsection 1.2.6, Tables 1.4 and 1.5). The outlier represented by a patient with MO 
COPD into the SE COPD class, was justified via the medical history. This patient’s FEV1% 
score indicated a closer value to the SE COPD group and a medical history which involved 
acute bronchitis, pulmonary embolism and asthma. 
 
3.4.5 | Discussion of Gender and Smoking Status 
The general analysis of the gender class was not consistent with the COPD gender analysis 
whatsoever. The literature falls into a disagreement regarding this subject, as there are studies 
which state that the males’ percentage that suffer from respiratory diseases predominates over 
the females group. Few of the reasons are based on the fact that male smokers prevail in 
comparison to female smokers, and they are more exposed to health damaging factors due to 
the nature of their occupations (Copes, Scott, 2007). Conversely, the proportion of females 
suffering from pulmonary disease has increased nowadays, and has reached an even level of 
that of males. Some of the consequences have shown to be triggered by household air pollution 
and an increased number of female smokers in the last decades (Anderson et al., 2001; Rajer 
et al., 2014).  
In the case of the smoking status analysis, the three classes of C (current smoker), E (ex-




these three classes. Nonetheless, the N class appeared to form a closer grouping than the C or 
E classes. 
 
  3.4.6 | Discussion of Outliers 
The outliers constituted the remarkable elements, as every class seemed to present at least one. 
Further investigation of each outlier has indicated that although it belonged to a certain class, 
its features matched more with different classes that it was attempting to join (exemplified by 
samples A112 and A135 HC, A067 COPD). These results indicate the impact of smoking status 
and medical history, the pack years and the type of life-style in general can affect a person 
similarly, indifferently of the diagnosis. 
 
3.5 | Conclusions and Future Research 
The Flow Infusion Electrospray Mass Spectrometry approach from this portion of work, has 
explored the lung metabolome with a view to investigate the differences between respiratory 
diseases from an easy-to-collect, minimally invasive and relatively inexpensive biofluid, 
saliva. Overall, all analyses have been successful or partially successful in discriminating 
between COPD, lung cancer and healthy patients. Moreover, with the addition of an extra group 
that involved other respiratory diseases such as asthma, idiopathic pulmonary fibrosis, 
pneumonia and bronchiectasis. 
Nowadays, saliva is increasingly promoted as a suitable alternative diagnostic biofluid to blood 
(Patel et al., 2014). However, its role in pulmonary diseases is yet to be clarified. Saliva has 
previously been used as a biosample for metabolomics in a study involving capillary 
electrophoresis mass spectrometry to generate oral, breast and pancreatic cancer outlines 




al. (2016), have demonstrated that saliva can deliver relevant metabolomics-derived 
biomarkers by employing the same metabolomics fingerprinting method of FIE-MS. This can 
have potential applications in the screening process for lung cancer patients.  
This segment of work attempted to encourage the use of saliva for further testing, as it can have 
potential in determining biomarkers through metabolomics fingerprinting techniques, without 
detecting individual metabolites. Additionally, the FIE-MS technique offers a fast sample 
classification based on their Mass Spectrometry m/z values.  
 
As an inconvenient point, this metabolomics fingerprinting method does not offer insight with 
regards to the biological processes that cause metabolome altering within the sample (Madsen, 
Lundstedt and Trygg, 2010). Therefore, the classification of disease groups is solely done on 
the peak masses (m/z) of samples.  
As future improvement, high AUC values identified in metabolites from this study, may offer 
the possibility to understand aberrations that cause relevant changes in the biological pathways 
of metabolomes in respiratory diseases. Nevertheless, metabolomics fingerprinting techniques 
have evidenced discrimination between groups of respiratory diseases such as lung cancer and 
COPD in comparison with healthy participants.  
Finally, results presented in this section of work have revealed insights into COPD, lung cancer 
and healthy patients, providing the ability to differentiate between their fingerprinting 
metabolites. Future work based on larger-scale patient cohorts, more defined diagnosis 
classification and a comprehensive set of all participant variables, would be required for a more 





CHAPTER 4 | Assessment of the Human Salivary Microbiome in Pulmonary Diseases 
 
4.1 | Introduction 
 It has been highlighted that the lung microbiome does not contain a large bacterial biomass as 
opposed to that of the lower gastrointestinal tract, however it still shows significant variety 
(O’Dwyer, Dickson and Moore, 2016).  
The upper respiratory tract, which comprises a considerable number of microbes, is directly 
linked to the lung (Wilson, Hamilos, 2014).  
Dickson et al. (2016) state that the lung is not sterile as it was believed a few decades ago, 
because it is constantly exposed to microbiota through inhalation or subclinical micro 
aspiration from birth. Additionally, healthy lungs are affected by physiological conditions that 
can influence bacterial proliferation i.e. oxygen tension, local pH, temperature or inflammatory 
cell disruption (West, 1978; O’Dwyer, Dickson and Moore, 2016). Studies on culture-
independent techniques of the healthy lung tissue (Morris et al., 2013; Bassis et al., 2015) 
mention Bacteroidetes and Firmicutes as predominant phyla. 
Interestingly, chronic lung diseases (as asthma, COPD, cystic fibrosis and IPF) have a great 
impact on the composition of the lung microbiome as well, by altering it. Bacterial population 
dynamics are altered by lung diseases, as a result of changes in the immigration of microbiota 
from lower to upper respiratory tract and elimination achieved by cough and mucociliary 
clearance - processes and local conditions of the lung’s microbial environment (O’Dwyer, 
Dickson and Moore, 2016).  
The lung microbiome represents a useful source for the assessment of lung diseases’ 
pathogenesis and inflammatory responses. The latter was tested in a study which compared 




community abundance of Prevotella and Veillonella (belonging to phyla Bacteroidetes and 
Firmicutes respectively) linked to high levels of WBCs (lymphocyte and neutrophil) (Segal et 
al. 2013).  
Moreover, in a study conducted on sputum samples of clinically stable COPD patients pair-
sampled with samples of exacerbation periods, increases in the relative abundances of 
Haemophilus, Pseudomonas and Moraxella bacteria were found (all belonging to 
Proteobacteria phylum). These results were discovered to be in connection with exacerbation 
episodes (Millares et al., 2014). Interestingly, Sze et al. (2012) in their sequencing-based tissue 
experiments from patients suffering of COPD, have reported an increase in the Firmicutes 
microbial community in severe COPD (GOLD stage IV) specifically. Therefore, changes in 
the lung microbiome due to exacerbations may be an adaptation to try to protect the lung from 
inflammatory responses and any potential respiratory viral infections.  
 
The human microbiota within the organs is primarily colonized by phyla such as 
Actinobacteria, Bacteroidetes, Cyanobacteria, Firmicutes and Proteobacteria (O’Dwyer, 
Dickson and Moore, 2016). 
Microbial changes that are relevant for respiratory diseases are not restricted to the lung only 
(Aas et al., 2005). The human oral cavity (Figure 4.1) comprises defined spatial regions with 
distinct microbiomes. It is comprised of the hard and soft palates, uvula and the tonsils, gums, 
the tongue and saliva to coat the mouth surface. According to Dewhirst et al. (2010), nearly 
600 microbial species have been identified within the human oral cavity. Many of which are 







Periodontal diseases, for instance, which are responsible for affecting the supporting structures 
of teeth, can trigger exacerbations in existing comorbidities such as cardiovascular and 
pulmonary diseases. The constituents of the oral microbiome in periodontal diseases are 
capable of undergoing host dysbiosis (microbial imbalance e.g. impaired microbiota within the 
body), which causes the whole clinical manifestation of the disease (Liu et al., 2012). 
Moreover, analysis of the oral microbiome of healthy patients and those suffering from 
periodontal disease revealed several metabolic pathways enhanced in the microbiome, which 
are associated with virulence factors. This resulted in a modification of the Gram-positive to a 
Gram-negative taxonomic domination in bacteria.  
The formation of biofilms within the oral cavity, mainly on the surface of the teeth, constitutes 
a good example of colonising bacteria which operate as frameworks for addition of other 
 
Figure 4.1 | Configuration of the Human Oral Cavity 
The structure of the human oral cavity is composed of several distinct structures such as the 
hard and soft palates, uvula and tonsils, the gums, tongue and ultimately saliva which do not 
have a fixed position within the cavity. Within this structure, saliva is produced by the three 





bacteria of the oral microbiome. According to Jenkinson and Lamont (2005), bacteria which 
act as frameworks include species from the Streptococcus and Actinomyces genera. These 
bacteria bind to salivary receptors that are able to coat uncolonised teeth surfaces. This process 
has been observed particularly in the Streptococcus bacterium which was revealed to bind to 
salivary proteins, such as -amylase, fibronectin and lactoferrin (Scannapieco, 1994). 
Consequently, species as Treponema and Candida were found as a constant addition to the 
microbiome framework. Thus, the microbiome plays an important role in oral diseases for 
exposing causative organisms.  
 
Saliva could be an ideal biofluid to sample the oral cavity. It does not have a set position within 
the oral cavity, and thus, could have microbial contributions from many parts of the upper 
respiratory tract. It also contains biomolecules such as enzymes, electrolytes, hormones, 
nucleic acids, peptides and proteins which are some of the main sources of sustenance for 
microbes from the oral cavity (Wickstrom and Svensater, 2008). Indeed, to exploit the 
diagnostic potential of the oral microbiome, Human Oral Microbe Identification Microarray 
(HOMIM), which consists of an oligonucleotide targeting specific 16S ribosomal Ribonucleic 
Acid (rRNA), has been developed. Screening of oral microbiota indicated alterations in the oral 
bacterial profile linked to pancreatic, oral and lung cancer, (Bonne and Wong, 2012; Huyghe 
et al., 2008, Farrell et al., 2012).  
However, the human salivary microbiome could differentiate from the microbiomes of other 
oral components including the gums, tonsils or tongue. Several phyla such as Actinobacteria, 
Bacteriodetes, Firmicutes, Fusobacteria and Proteobacteria have been shown to dominate the 




Streptococcus and Veillonella account for the majority of the microbiome in culture-
independent sequencing (Segata et al., 2012).  
 
Saliva may be a promising biosample for the detection of microbiome-derived biomarkers for 
several diseases. Changes between the oral microbiome in a wide range of respiratory diseases, 
has yet to be fully determined. Work in our group has examined seasonal alterations in the 
saliva microbiome of healthy volunteers focusing on bacterial load and pH as well as estimated 
bacterial load and pH indicated significantly (P <0.001) higher levels during winter and spring 
(Cameron et al., 2015). The study also included the 16S rRNA (V3 and V4) amplicon 
sequencing based on DNA extracted from saliva. Results  showed significant differences 
between participants at phylum level. The most notable pathogenic bacteria phyla detected 
include Actionobacteria (P <0.001), Bacteriodetes (P <0.001), Fusobacteria (P <0.001), 
Proteobacteria (P <0.001), Synergistetes (P <0.001), Firmicutes (P =0.008), and Spirochaetes 
(P =0.003).   
 
 
4.1 | Objectives 
In this portion of work, DNA extracted from human saliva samples from patients that were 
suffering of pulmonary diseases and healthy controls, were analysed in order to observe 
changes in bacterial load of the human microbiome and determine their taxonomic abundances. 
Moreover, this study was also aimed to assess human saliva as a potential biosample that can 





4.2 | Materials and Methods – Microbiomics Analysis 
 
4.2.2 | Patient Recruitment and Saliva Sampling 
The patient recruitment and saliva sampling from this section corresponds with subsection 
3.2.1. Samples were centrifuged and the supernatants used for metabolomic analysis as 
described in Chapter 3. The pellets of the saliva samples were stored at -80 C in the freezers 
of IBERS at Aberystwyth University until needed. The pellets used for DNA extractions were 
employed in experiments for Quantitative Polymerase Chain Reaction (qPCR) bacterial load 
and 16S rRNA (V3 and V4) amplicon sequencing.  
 
4.2.3 | Processing of Raw Saliva and DNA Extraction 
The protocol used was adapted from Cameron et al. (2015). All saliva samples donated by the 
participants underwent centrifugation at 10,000 x g, at 4C for 10 minutes. Total genomic DNA 
was extracted from 200 l of saliva pellet using the FastDNA Spin Kit for Soil (MP 
Biosciences, USA). Following the manufacturer’s instructions, prior to starting the sample 
processing, exactly 100 ml of 100% ethanol was added to the Salt/Ethanol Wash Solution 
(SEWS-M) wash solution. SEWS-M is an ethanol-based wash solution used to wash away 
impurities once the DNA is bound to the Binding Matrix. 
 All saliva samples (74) were normalised to ensure 40 ng/l DNA per sample, then centrifuged 
(Multifuge 3 S-R Heraeus) at 4,600 rpm at 21C for two minutes. The normalisation process 
consisted in subtracting every value of quantified DNA from five, which was the “final 
concentration ultrapure water”, in order to obtain the dilution factor. Each volume of DNA 
needed to add in order to make up the 40 ng/l concentration, was obtained by multiplying the 




obtained by subtracting the previously obtained volumes of needed DNA from 40. From this, 
200 l of each sample was pipetted into its corresponding Lysing Matrix E tube to which 978 
l Sodium Phosphate Buffer has been added to induce cell lysis process. Following this, 122 
l MT buffer were added to protect and solubilize the nucleic acids following cell lysis. All 
samples have been homogenised for 30 seconds at a speed setting of 6.0 in a FastPrep 
Instrument (24 MP Biomedicals, USA). Samples were then placed on ice for 30 seconds and 
homogenised again in the FastPrep Instrument at the same settings. These latter steps were 
repeated once more and after the samples were subjected to centrifugation (Thermo Scientific 
Heraeus Pico 21 Microcentrifuge) at 13, 000 x g for 10 minutes to pellet the debris. 
The supernatant of every sample was then transferred to an individual clean 2.0 ml 
microcentrifuge tube to which 250 l Protein Precipitation Solution (PPS) were added and then 
mixed by shaking the tube by hand 10 times. The PPS is used as a stabilization agent during 
sample lysis and homogenization of subsequent extraction and purification of nucleic acids. 
The supernatant underwent centrifugation once more at 13, 000 x g for five minutes to allow 
the pellet to precipitate and then transferred to a clean 5 ml Vulcan tube. 
Exactly 1 ml of the re-suspended Binding Matrix suspension was added to the supernatant of 
each sample in the Vulcan tube. The samples were then placed on a rotator (Vortex Genie 2 
Shaker) for two minutes to allow binding of DNA. The tubes were then put on a rack for three 
minutes to allow the silica matrix to settle.  Following, 500 ml of the supernatant was removed 
and discarded, being careful to avoid the settled Binding Matrix.  
The remaining amount of the Binding Matrix and supernatant from each tube was resuspended 
and approximatively 600 l of this mixture was transferred to a Spin Filter and subjected to 




remaining mixtures from the Vulcan tubes were added to the Spin Filters and centrifuged as 
before. The catch tube was emptied again.  
Exactly, 500 l of the previously prepared SEWS-M wash solution, was added to the Spin 
Filter by gently resuspending the pellet using the force of the liquid from the pipette tip. The 
samples were subjected to centrifugation at 13, 000 rpm for two minutes and the catch tubes 
were emptied and replaced with new ones.  
Without any addition of liquid, the samples were centrifuged a second time  at 13, 000 x g for 
two minutes and then left at room temperature so that the matrix and residual wash solution 
can air dry. The catch tube was discarded and replaced with a new one.  
The Spin Filters with the samples were left to air dry at room temperature for five more minutes. 
Then, the Binding Matrix from the Spin Filter was resuspended in 50 l of DNA Elution 
Solution (DES) in order to wash away the unbound proteins. Finally, the samples were 
subjected to centrifugation at 13, 000 x g for two minutes once more, to bring eluted DNA into 
the clean catch tube and the Spin Filters were discarded. 
 
4.2.4 | DNA Quantification and qPCR Standards Preparation 
The resulting DNA from the extractions process was then quantified in duplicates using an 
Epoch Microplate Spectrophotometer (BioTek). Following the DNA quantification process, 
four DNA samples were chosen according to their highest values ng /l. These samples were 
(concentrations and clinical diagnosis of the patient from which the sample was obtained are 
shown) C012/COPD – 413 ng/l, A133/HC - 317 ng/l, A149/HC - 230.4 ng/l and A001/HC 




These were used to create standards that will be further used in the quantitative Polymerase 
Chain Reaction (qPCR) experiment. 
To derive the standards, the following PCR conditions were used. Each 22.5 l reaction volume 
consisted of 2.5 l of the five neat DNA template or the non-template controls (NTC), 12.5 l 
of  2 X BioMix (BioLine), along with 7 l PCR Grade Water (Roche, Sigma Aldrich), 0.25 l 
of 27f primer (5’-AGA GTT TGA TCC TGG CTC AG-3’) and 0.25 l of 1389r primer (5’-
ACG GGC GGT GTG TAC AAG-3’) of 10 M concentration. 
The reaction volumes were then subjected to a Thermal Cycler PCR machine (BioRad) at the 
following cycles: one activation cycle for 120 seconds at 94C; 30 cycles consisting of 
denaturation for 45 seconds at 94C, annealing for 45 seconds at 55C and elongation for 90 
seconds at 72C; one cycle of final elongation step for seven minutes at 72C and refrigeration 
until further processed at 4C. 
 
4.2.5 | Agarose Electrophoresis for DNA Extraction from Gel 
After running the PCR program with the samples chosen as standards, the DNA samples were 
loaded onto an agarose gel electrophoresis in order to confirm the length of the 16S rRNA 
DNA fragment.  
Exactly one gram of agarose Electrophoresis Grade (Melford Laboratories, UK) was weighted 
to which 100 ml of 0.5 Tris-acetate-EDTA (TAE) were added and mixed vigorously on a 
magnetic stirrer (Fisher Scientific, USA). Then, the mix was heated in the microwave 
(Panasonic NN-7543W) until the agarose melted. To this, 7.5 l of gel stain (SYBR Safe DNA 





Further on, the gel tray was placed into the casting chamber and the comb was positioned into 
the appropriate slot in order to pour the already prepared agarose. The gel was then left to set 
for approximatively 30 minutes. 
 Exactly 2 l of 6X Blue/Orange Loading Dye (Promega Madison, USA) were pipetted along 
with 5 l of the four chosen DNA samples and a negative PCR (without template). Each dot of 
dye and DNA were mixed with pipette tips and then loaded into the corresponding wells of the 
gel. The first well was loaded with 1 l of 1 kilobase (kb) HyperLadder (BioLine). The 
electrophoresis machine (BioRad Power Pac Basic) was then set for 75 minutes at 65 Volts 
(V). 
  
After the electrophoresis step, the agarose gel was scanned in the Gel Doc XR machine 






Following, each band of DNA was cut from the gel under the UV light of the Transilluminator 
machine (DR-195M Colorado, USA). The amplified fragments were excised from a gel using 
a scalpel and placed in a previously weighed microcentrifuge tubes. This was then weighed 
once more.  
The weight of the gel is directly proportional to its liquid volume and this was used to determine 
the amount of QX1buffer (Qiaex II Gel Extraction Kit, Qiagen, 2011) that needed to be added 




Figure 4.2 | Electrophoresis Gel Result of DNA from Human Saliva 
One kb HyperLadder expressed in bp and ng/BAND on the left-hand side and then (moving to 
the right) each of the DNA fragments obtained from amplification of a Gene Pool mix of these 
four samples: C012, A133, A149 A001. The fragment  is the expected  ~ 1300 bp in size. A 
final seventh well with the PCR with negative control with no template DNA yielded no visible 
fragment. 




Table 4.1 | Determination of QX1 buffer amounts to extract the DNA fragment  
The QX1 buffer volumes were obtained by subtracting the weight of the empty tube from 
the weight of the tube with the gel fragment. The resulting amounts were multiplied by 3 as 
















buffer to add 
(l) 
1 1.24 1.11 130 3 390 
2 1.30 1.12 180 3 540 
3 1.34 1.13 210 3 630 
4 1.37 1.12 250 3 750 
 
 
Estimating that all DNA samples have in between 2 – 10 g, exactly 30 l of QIAEX II were 
added to each tube labelled 1 to 4 to bind the DNA. Afterwards, the samples were incubated in 
the Water Bath Machine (Clifton, UK) at 50C for 10 minutes so the agarose can solubilize 
and bind the DNA. Within these 10 minutes, the samples were vortexed every two minutes in 
order to keep the QIAEX II in suspension. This step was repeated five times within the 10 
minutes of the water bath process. The resulting colour mixture was yellow which indicated a 
pH of  7.5. 
The samples were then centrifugated at 13, 000 rpm for 30 seconds and the supernatant was 
removed. The pellet was washed with 500 l buffer QX1 and resuspended by vortexing. Then, 
the samples were subjected to centrifugation once more for 30 seconds and all traces of 
supernatant were carefully removed. This wash step was done in order to remove residual 
agarose contaminants. Next, the pellet was washed twice with 500 l buffer PE and 
resuspended by vortexing. Then, it was centrifuged again for 30 seconds at 13,000 rpm and all 
traces of supernatant were carefully removed. This step was performed twice. The PE buffer 
prevents DNA from dissociating from the column while also serving as a useful wash to remove 




The pellets were then air-dried for approximately 30 minutes until the pellet became white. To 
elute the DNA, 20 l of deionised water was added and the pellet was resuspended by 
vortexing. The resulted pellets were left at room temperature for five minutes with the lids 
uncapped. 
Finally, the samples were centrifuged for 30 seconds at 13, 000 rpm and the supernatant was 
transferred into a new clean tube. This now contained the purified DNA.  
Samples with extracted DNA were then quantified using an Epoch machine (BioTek, UK) and 
normalised to 5 ng/l. 
Following, from the gene pool values obtained by quantification the number of molecules 
(copies of template in the sample) were calculated from the formula:  
Number of copies = 
𝑎𝑚𝑜𝑢𝑛𝑡 (𝑛𝑔) 𝑥 6.022 𝑥 10^23
𝑙𝑒𝑛𝑔𝑡ℎ (𝑏𝑝) 𝑥 1 𝑥 109𝑥 660
 therefore, Number of copies = 
59.8 𝑥 6.022 𝑥 10^23
1342 𝑥 1 𝑥 109𝑥 650
 
= 4.13 x 1010. 
From the tube containing the extracted DNA, exactly 2 l was transferred into a tube already 
containing 20 l deionised water and mixed with the pipette tip. The sample was then vortexed 
and centrifuged. This sample constituted the first standard value of 101.  From the 101 standard, 
10-fold serial dilutions of 102, 103, 104, 105, 106, 107 were made for the qPCR experiment.  
 
4.2.6 | 16S rRNA Quantitative PCR Set-Up 
Numerous attempts at qPCR were made using different DNA and primer concentrations, 
agarose confirmation gels of the primer quality and different batches of SYBR Green. 
However, none were successful in achieving a normal amplification curve (Figure 4.3). This 
could be due to several factors that inhibited the efficiency of the reaction: poor primer design, 




(primer-dimer) and/or lack of specificity of the DNA-binding SYBR Green dye (Bio-Rad 
Laboratories, 2006). 
 
Figure 4.3 | (A) Expected amplification plot of the Quantitative PCR experiment and (B) Standard 
Curve generated by plotting the starting quantities (sometimes expressed as normalised Log10 
values) against the Cycle Threshold (Ct). Photo retrieved from Real-Time PCR Guide, Bio Rad, 2006. 
 
Finally, the standard DNA samples were extracted from a whole genomic  Escherichia coli (E. 
coli) culture which gave the expected results.  
The qPCR experiment was prepared under a fume cupboard in a 96-well plate in duplicates for 
each sample including standards and no template controls (NTC). Each reaction volume of 
11.28 l consisted of 5 l SYBR Green the DNA binding dye, 0.04 l EubF1 primer (5’-GTG 
STG CAY GGY TGT CGT CA-3’) and 0.04 l EubR1 (5’-ACG TCR TCC MC ACCT TCC 
TC-3’) both of 10 M concentration, 3.20 l PCR Grade Water and instead of adding 1 l of 
DNA as in the previous experiments, 3 l were added. For the NTC sample, the DNA was 
replaced with PCR Grade Water.  
The qPCR machine used was Light Cycler 480 II Roche, under the following settings: one 




40 cycles of annealing for 60 seconds at 60C, followed by a melt curve consisting of a 
temperature gradient of 60 to 95C in 0.5C increments, each for five seconds. 
 
4.2.7 | 16S rRNA Quantitative PCR Data Analysis 
Estimates of the bacterial load from saliva were calculated through qPCR, using the 10-fold 
serial dilutions of 16S rRNA gene standards.  
The qPCR cycle number is displayed on the x-axis and the fluorescence detected during the 
amplification reaction, on the y-axis. The fluorescence is directly proportional to the amount 
of amplified product; therefore, it gets measured in each cycle. The threshold cycle (CT) is the 
cycle number at which detectable signal is achieved. It is determined by the amount of template 
present at the start of the amplification reaction (Bio-Rad Laboratories, 2006).  
In this experiment, results indicated a variety of both high and low CTs as shown in Figure 4.5. 
The standard curve for the bacterial load was constructed by plotting the log of the dilution 
factor of the starting quantities against the CT values from the amplification of each dilution.  
From this, the equation of linear regression line, the coefficient correlation (R2) and the slope 
(m) were calculated from the following: y = mx + b,  
resulting in y = -3.5862x + 42.933 with a coefficient correlation of R² = 0.9154.  
By knowing the slope value, the efficiency (E %) was determined from the following:  
%E = 10-(1/slope),  
therefore 10-(1/-3.5862) = 1.9 and  





4.2.8 | 16S rRNA Amplicon Sequencing Set-Up 
Sequencing of the 16S rRNA gene was carried out through amplification of the V3 and V4 
region. Following, amplicon sequencing on the Illumina MiSeq instrument was performed. 
Initially, the V3 and V4 region of the 16S rRNA gene was amplified via duplicate PCR with 
locus specific primers. PCR Grade Water was utilised as negative control. 
Each reaction of 25 l volume, consisted of 12.5 l 2X Accuzyme Mix (BioLine), 5 l of 806r 
PCR Primer (5’-GAC TAC HVG GGT ATC TAA TCC-3’ with Illumina reverse overhang 
adapter sequence 5’-GTC TCG TGG GCT CGG AGA TGT GTA TAA GAG ACA G-3’), 319f 
PCR Primer (5’-CCT ACG GGN GGC WGC AG-3’ with Illumina forward overhang adapter 
sequence 5’-TCG TCG GCA GCG TCA GAT GTG TAT AAG AGA CAG-3’) each of 1 M 
concentration and 2.5 l normalised DNA as detailed by Klindworth et al., (2013). 
The V3 and V4 are two of the nine “hypervariable regions” of the bacterial 16S rRNA, which 
have been shown to possess significant sequence diversity among certain bacteria (Chakravorty 
et al., 2007). These two hypervariable regions of 16S rRNA were employed in phylogenetic 
classifications of the microbial populations within human saliva. The overhang adapter 
sequences were added to the 806r and 319f primer pair sequences for compatibility with the 
Illumina index (designed by Cameron, 2015) displayed in Supplementary Table 4.1.  
 
Reactions were run under the following PCR conditions: one cycle activation for 10 minutes 
at 95C, followed by 25 cycles of denaturation for 30 seconds at 95C, annealing for 30 seconds 
at 55C, elongation for another 30 seconds at 72C, and five minutes for final elongation at 
72C as well, then held at 4C. Each PCR product was confirmed through visualisation on a 





Following confirmation of accurate PCR results, the reaction volumes were purified using the 
AMPure beads (Agencourt Qiagen) clean-up to remove adapter dimers and confirmed on an 
agarose gel once more (Figure 4.4).  
 
These further steps were performed with the help of Dr Matthew Hegarty - IBERS 
Translational Genomics Facility Gogerddan. After the dimer purification step, one last PCR 
program was run to attach Illumina adaptors to amplified products. This step allows 
multiplexed amplicon sequencing on the Illumina MiSeq platform. The final reaction volume 
of 25 l, constituted of 2.5 l of the purified PCR product obtained in the previous step, 12.5 
l of 2X Accuzyme Mix (BioLine), 5 l of PCR Grade Water (Roche), 2.5 l of the relevant 
Nextera XT Index Primer1 (N7) and Nextera XT Index Primer2 (S5) from Illumina 
(Supplementary Table 4.1) (Cameron, 2015). Subsequently, the reaction mix was subjected to 
a PCR program consisting of three minutes at 95C, eight cycles of 30 seconds at 95C and 30 
seconds at 55C, followed by a final elongation step of five minutes at 72C. Following, the 
entire reaction volume was verified on a 1% agarose gel, the PCR products excised from it and 
 
A 
Figure 4.4 | AMPure clean-up to check the change in size of the DNA sequence after adding 




purified using an Isolate II PCR and Gel Extraction kit (BioLine) following manufacturer’s 
instructions.  
 
4.2.9 | 16S rRNA Amplicon Sequencing Data Analysis 
Further processing of samples was carried out at the IBERS Translational Genomics Facility 
Gogerddan from Aberystwyth University with the help of Dr Matthew Hegarty. The sample 
libraries obtained were pooled together in equimolar concentration. Following, these were 
sequenced with 20% PhiX DNA as control for low diversity on the Illumina MiSeq platform 
using MiSeq V3 reagents for a 2 x 300 bp paired end sequencing.  
After sequencing, the reads were merged and compressed, then subjected to the MG-RAST 





4.3 | Results 
 
4.3.1 | 16S rRNA Quantitative PCR 
Initial studies sought to test if there were any changes in bacterial load of the saliva samples 
from respiratory disease patients by qPCR.  The standards curve obtained derived producing 
an almost perfect doubling for each amplification cycle and a linear standard curve, confirming 
the 10-fold serial dilution of DNA with an R2 confirms a value of 0.915 (Figure 4.5). 
Subsequent results obtained from the qPCR analysis of the saliva samples were transferred to 




samples were calculated by constructing an absolute standard curve against the known 
standards of the E. coli DNA concentrations. 
 
Figure 4.5 | Absolute quantification of E.coli standard curve for reaction optimization of 
unknown bacterial load in DNA from saliva samples 
Standard curve generated for the quantities of 16S rRNA gene copies (bacterial load) from saliva 
samples were obtained by plotting the log of the starting quantity template of  E. coli DNA against 
the CT values from the amplification of each unknown saliva sample. The equation of the regression 
line and the coefficient correlation (R2) are displayed on the graph above. The calculated 
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Absolute Quantification of E. coli Standard Curve and Saliva Bacterial Load
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Based on the derived standard curve the bacterial load for each experimental class was 















S13 A055 COPD current 35 No 








S33 A095 HC never  N/A No 




S27 A088 HC never  N/A No 




S30 A091 HC never  N/A Yes 
S34 A101 COPD never  N/A Yes 








S32 A094 LC current 40 Yes 
S31 A093 HC never  - No 
S38 A112 COPD current 45 Yes 
S24 A079 HC never  - No 




S23 A078 HC never  - No 
S15 A059 HC current 80 Yes 












S37 A123 HC current 13 Yes 




S14 A086 HC never  - No 
S20 A058 COPD current 30 No 
S17 A071 COPD current 50 Yes 









Table 4.2 | Quantitative PCR sample order of the Absolute Quantification Analysis containing 
Sample ID, Diagnosis Class, Smoking Status and Pack Years recorded per patient during 
recruitment  
Samples in decreasing order as displayed in Figure 4.5, starting from the highest concentration of the 








Analyses of bacterial loads in saliva indicated that the samples obtained from COPD patients 
which were undergoing an exacerbation (EXAC) had significantly lower loads than any other 
category. Saliva from healthy controls (HC), non-exacerbating COPD patients (COPD) and 






Figure 4.6 | Bacterial load in DNA from saliva samples from respiratory patients and 
healthy controls 
Mean bacterial loads for healthy controls (HC) and patients with base-line chronic 
obstructive pulomonary disease (COPD), COPD patients which were undergoing an 
exacerbation (EXAC) and lung cancer (LC) patients. Significance groups (P <0.05) as 
























4.3.2 | 16S rRNA Amplicon Sequencing Results 
The following analyses were carried out with the help of my supervisor Luis Mur – IBERS, 
Aberystwyth University.  
The V3 to V4 regions of 16S rRNA genes of the microbial genomes of the DNA samples were 
sequenced using the MiSeq Illumina platform following a paired end approach. Derived 
sequences were assembled and analysed against the SILVA (High Quality ribosomal RNA) 
database (Quast et al., 2013) to identify the derived Operational Taxonomic Units (OTUs) 
using the European Nucleotide Archive (ENA) pipelines (Meyer et al., 2008).   
The number of paired reads for each sample is given in Figure 4.7. Subsequently, the matrix 
generated by the ENA platform was interrogated using the Microbiome Analyst Platform 
(Dhariwal et al., 2017). 
 
Initial analyses focused on establishing if there was a core microbiome in all saliva samples 
(Figure 4.8). Only Streptococcus was prevalent in every saliva sample. The data were next 








Figure 4.7 | Pair-end reads for each saliva sample with their corresponding Sample ID and 
Diagnoses 
This step classified the groups of the Operational Taxonomic Units (OTUs) according to the 16S Bacterial 






Figure 4.8 | Prevalence of OTUs in the saliva dataset 








Figure 4.9 |   Assessing variation in the microbiome linked to experimental classes and 
displayed as a (A) dendrogram and (B) Principal Coordinate Analysis (PCoA) with 
estimates of significance derived by PERMANOVA  
Permutational multivariate analysis of variance compared COPD, COPD (Exac), HC and LC 





This was also clearly indicated by a significant reduction in the a-biodiversity in the COPD 
exacerbator group. Alpha diversity captures both the organismal richness of a sample and the 
evenness of the abundance distribution.  Similar observations were made when analysing at the 
genus (Figure 4.11) and species (Figure 4.12) classification levels.  
 
Figure 4.10 | Classification of the means of phyla taxonomy for 16S rRNA sequencing of the four 
classes COPD, LC, HC and Other 
Individual variation of the bacteria phyla abundances was identified in the DNA samples from human 
saliva, through the European Nucleotide Archive (Meyer et al., 2008) platform. Bacterial phyla displayed 
significant different abundances between the four groups of COPD, Healthy Control, Lung Cancer and 







Figure 4.11 | Sample classification based on the means of genus taxonomies for 16S rRNA 
sequencing of the four classes COPD, COPD Exacerbation, LC and HC 
(A) Variation of the bacterial genomic class abundances was identified in the DNA samples from 
human saliva, through the European Nucleotide Archive platform (Meyer et al., 2008). Bacterial 
genera displayed significant different abundances between the four groups of COPD, COPD 







The lowest classification level OTUs could be identified (as shown by the low number of NA’s 
= no OUT abundance threshold applied) were at the genus level; differences between the 
experimental classes were plotted (Figure 4.13).  
 
PCA of the genus level further indicated that the COPD exacerbator group was distinctive 
(Figure 4.13A). ANOVA of the genus level identified 11 genera which significantly differed 
between the experimental classes. These were plotted in a heat map for individual samples 
(Figure 4.13B) and as the average for each experimental class (Figure 4.13C). These analyses 
clearly indicated that the COPD exacerbation stage was associated with a loss in a range of 




















Figure 4.12 | Classification of the means of species taxonomy for 16S rRNA sequencing of the 
four classes COPD, COPD Exacerbation and HC  
 (A) Individual variation of the bacteria species abundances was identified in the DNA samples from 
human saliva, through the European Nucleotide Archive (Meyer et al., 2008) platform. Bacterial 
species displayed significant different abundances between the four groups of COPD, COPD 











To demonstrate the variation in individual genera amongst the different experimental classes 




Figure 4.13 | Identifying genera which differed according to experimental class COPD, 
LC, HC and COPD Exacerbation (EXAC) in human saliva 
 (A) PCA of genera abundance (B) Plot of a heat map and dendrogram of genera showing 
significant (P <0.05) variation between the classes as defined by ANOVA and plotted for each 
sample (C) Heat map and dendrogram of the averages of genera showing significant (P <0.05) 





Figure 4.14 | Plots of genera that showed significant (P <0.05) variation between the 
experimental classes as defined by ANOVA 
 
Figure 4.14 confirmed that in the vast majority of genera, they were significantly reduced at 
the exacerbation stage (in the COPD group), the one exception being Staphylococcus. Plotting 
the species of Staphylococcus that were detected in the saliva microbiome, this increase 
appeared to be linked to changes in S. aureus which was by far the most abundant 






S. aureus is frequently found in the nose, respiratory tract, and on the skin. S. aureus is an 
important cause of pneumonia, but in upper respiratory tract often exists as a ‘pathobiont’ in 
that they colonize the host asymptomatically. Such pathobionts include Streptococcus 
pneumoniae, Haemophilus influenza, as well as Staphylococcus aureus. However, these can 
still cause disease as people age, are hospitalised or are smokers (Schenck et al., 2011). It is of 
relevance that COPD is a risk factor in initiating S. aureus –mediated pneumonia (Wooten et 
al., 2013).  However, increases in S. aureus – changes have not been previously described in 
the saliva of COPD patients. Increases in S. aureus may reflect interactions with other species 
such as the fungus Candida albicans. S. aureus is known to form multispecies biofilms with 
C. albicans to help penetrate human tissue (Schlecht et al., 2015).  
The loss in bacterial diversity is a major feature of COPD exacerbation posing the question of 
why this should be the case.   
 
The following is a summary of some of the features of the bacterial genera which differentially 
accumulated between the COPD exacerbator and other classes.  
Some genera include opportunistic pathogens as Actinomyces, which are commonly found in 
the gums and can lead to the opportunistic infections of the oral cavity and rarely cause 
Actinomycosis which leads to the formation of abscesses in the mouth or lungs; 
Capnocytophaga is a commensal species common to the oropharyngeal tract of mammals. 
However, it can be involved in infections depending on the immune status of the patient. In 
Table 4.3 | Percentage of Staphylococcus species in each experimental class  
Group Aureus Epidermidis Haemolyticus Equorum Pettenkoferi Sciuri Succinus 
COPD 99.76666 0.211947 0.020741 0.01 0.01 0.000648 0.01 
EXAC 99.98756 0.001422 0.000356 0 0.000711 0.005511 0.004445 
HC 99.90245 0.088344 0.006699 0.000419 0 0.002093 0.01 





immunocompetent patients, it could contribute to periodontal infections occasionally leading 
to apical and periodontal abscesses (McGuire & Nunn, 1996). 
Gemella are found in the mucous membranes of airways and have been linked to exacerbations 
in cystic fibrosis patients (Carmody et al., 2013).  
Granulicatella genus is known to be a normal flora of the upper respiratory and gastrointestinal. 
It has been linked to diseases like Endocarditis and Bacteremia, but it is noted that in lungs it 
increases in the sputum of LC patients (Cameron et al., 2017). A similar increase in the saliva 
of LC patients was not observed.  
Other bacterial genera appear more benign. Rothia is considered a part of the normal flora of 
the human oropharynx and upper respiratory tract and not associated with disease. Botyvibrio 
is commonly associated with the gastro-intestinal tract (GI) tract but have been noted to occur 
in the mouth (Segata et al., 2012). However, it has not been associated with a respiratory tract 
pathology.  
Coprococcus has also been linked to maintaining gastro-intestinal health but there is no 
evidence any role in the oral cavity (Backhed et al., 2015). Similarly, Moryella and 
Ruminococcus has not been previously associated with the oral cavity.  
Considering the data together, it can be seen that reduction in the numbers of certain genera 
cannot be linked to any abilities to act as an opportunistic pathogen or respond to host immune 
status. Instead, it seems likely that this could reflect patients being treated with antibiotics. This 
would also agree with the reduction in overall bacterial load seen in the COPD exacerbator 
group.  Given that S. aureus is breaking this trend it may be that antibiotic treatments are 
selecting for resistant bacterial strains of a significant pathogen in the oral cavity.   
S. aureus is not the only species to increase in the exacerbator category. Although species data 




Lactobacillus casei. This species is a facultatively anaerobic species and possess a strictly 
fermentative metabolism with lactic acid as the major metabolic end product (Axelsson, 1998).  
This would suggest a change to anaerobic respiration in the upper respiratory tract of COPD 
patients suffering of exacerbations towards the increased prevalence of bacterial species which 
are tolerant to higher levels of lactic acid.  
 
4.3.2 | COPD Stage Specific Microbiome Changes 
Given the observed difference between the non-exacerbator and exacerbator categories (e.g. 
Figure 4.14), the salivary microbiomes were assessed for differences that aligned with COPD 
stages; MILD (MI), MODERATE (MOD), SEVERE (SEV) and VERY SEVERE (VS), 
EXACERBATOR (EXAC) and HEALTHY CONTROL (HC) (Figure 4.15). 
PCA of genera abundance suggested that the EXAC category remained the most distinctive 
(Figure 4.15A). ANOVA identified genera which significantly differed between the COPD 
categories and when displayed on a heat map (Figure 4.15B), this also indicated that only the 





These data were also plotted for mean values for each bacterial genus for each COPD category 
(Figure 4.16). This indicated three patterns of response to progressive COPD; an increase seen 
only in the EXAC category (Figure 4.16B) and seen only on S. aureus; progressive reduction 
 
 
Figure 4.15 | Identifying genera which differed according to COPD classification MILD (MI), 
MODERATE (MOD), SEVERE (SEV) and VERY SEVERE (VS) and Healthy controls (HC)  
(A) PCA of genera abundance in each COPD classification (B) Plot of a heat map and dendrogram of genera 





in abundance as COPD progresses (Figure 4.16C) and finally, those which exhibited a 
significant reduction only in the EXAC category (Figure 4.16D).  Such very different types of  
response to progressive COPD would argue for specific responses to patient treatment 







Figure 4.16 | Genera that showed significant (P <0.05) variation between the COPD experimental classes 
as defined by ANOVA  
Results were plotted as (A) heat map of mean values and box and whisker of (B) genera showing increases in the 
COPD exacerbator class (C) general showing progressive decreases in abundance as COPD progresses and (D) 




4.3.3 | Saliva Microbiome and Lung Cancer 
Given the microbiomic changes that were occurring in the COPD stages (Figure 4.16), possible 
differences linked to LC were examined. Focusing on genera, PERMANOVA failed to 
demonstrate any significant differences occurring with lung cancer (Figure 4.17). 
The genera with the LC and HC categories were plotted (Figure 4.18), but these did not exhibit 




Figure 4.17 | Assessing variation in the microbiome genera linked to Lung Cancer (LC) 
and Healthy Controls (HC) displayed through Principal Coordinate analysis (PCoA) 






Figure 4.18 | Features in the microbiome genera linked to Lung Cancer (LC) and healthy 





4.4 | Discussion  
Due to the easiness in sampling and possible usefulness in disease biomarkers, human saliva 
has potential to be a valid biofluid for future microbiomic analyses. Previous studies have 
managed to demonstrate that human saliva may offer understanding on insights of cancer 
diseases such as oral, breast and pancreatic (Sugimoto et al., 2010), on obesity (Matias et al., 
2012) and dental caries (Yang et al., 2012). 
In this segment of work, the salivary microbiome of 74 patients was sampled over a seven-
month period. All samples underwent 16S rRNA amplicon sequencing (V3 – V4) to identify 
the taxonomic composition of their salivary microbiome. Additionally, the estimated salivary 
microbial load was measured on a group of 28 patients. 
 
4.4.1 | Bacterial Load 
The bacterial load of human saliva may have potential to be a marker of immunity and an 
indicator of bacterial levels throughout seasonal changes or severity of disease (Jones et al., 
2014). Moreover, the salivary bacterial load has indeed been suggested to originate from other 
causes i.e. respiratory diseases than dental conditions as gingivitis and/or periodontal disease 
(Mantilla Gomez et al., 2001).  
In this portion of work, human saliva was assessed as a potential biosample source for the 16S 
bacterial microbiome through the qPCR analysis. As displayed in Figure 4.5 and detailed in 
Table 4.2, saliva samples that contained higher levels of bacterial load belonged mostly to HC 
participants or patients that were not undergoing antimicrobial treatment. Variables such as 
smoking status and pack years did not seem to influence the outcome of the bacterial load 
analysis. Patients that were on antibiotic medication at time of recruitment displayed lower 




These results were in agreement with the findings of Erb-Downward et al. (2011) who used 
16S pyrosequencing analysis to examine four COPD patients, seven healthy smokers and three 
non-smokers. The outcome did not indicate a significant differentiation between the lung 
microbiomes of the three groups. However, the lung microbiome diversity of the COPD 
patients was shown to be reduced in comparison to healthy smokers.   
Similarly, the bacterial load analysis conducted on the HC, COPD, COPD Exacerbation and 
LC experimental classes (Figure 4.6) indicated patients which were undergoing an 
exacerbation had significantly lower loads when compared to the other categories.  Therefore, 
such observations suggest that imposing stress on the lung via smoking or certain pathological 
situation, such as COPD exacerbations, results in a reduction in certain bacterial populations. 
This could arise from inflammatory or immunological responses in the lung and may be 
associated with reduced lung function under both situations. Equally, it could be that the altered 
lung function itself may influence the lung microbiome.  
 
4.4.2 | Amplicon Sequencing 
The initial analysis of the core microbiome has shown that Streptococcus was prevalent in 
every saliva sample (Figure 4.8). The permutational multivariate analysis of variance indicated 
the COPD Exacerbation class as the most distinctive (Figure 4.9). These differences were 
assessed at different levels of taxonomic classification: phyla, genus and species.  
The bacterial genera and species displayed similar bacterial abundances between three 
experimental classes COPD, HC and LC, but significantly different abundances in the COPD 
Exacerbation group. The COPD Exacerbation class was associated with a loss in a range of 
bacterial genera. However, it displayed an increase in the Staphylococcus genus (Figures 4.11 




Interestingly, S. aureus was by far the most abundant out of the Staphylococcus species in all 
saliva samples (Table 4.3). Increases in S. aureus may reflect interactions with other species 
such as the fungus Candida albicans, in forming multispecies biofilms with it to help penetrate 
human tissue (Schlecht et al., 2015). The loss in bacterial diversity is a major feature of the 
COPD exacerbation class, posing the question of why this should be the case.  
The relative abundance analysis of LC and HC genera (Figure 4.18) has not exhibited great 
differences between the two groups and the −diversity measurement displayed a reduction in 
the LC group in comparison with HC class.    
 
 Considering the data together, there is the possibility that the reduction in the numbers of 
certain genera cannot be linked to any abilities to act as an opportunistic pathogen or respond 
to host immune status. Instead, it may reflect the outcomes of patients being treated with 
antibiotics. This would also agree with the reduction in overall bacterial load seen in the COPD 
Exacerbator group. Given that S. aureus is breaking this trend it may be that antibiotic 
treatments could be selecting for resistant bacterial strains of a significant pathogen in the oral 
cavity.  On the other hand, the alteration in microbial community content during exacerbation 
episodes may be an adaptation in trying to protect the lung from respiratory viral infections. 
A more in-depth perception of pathogenic bacteria in relation to respiratory diseases and 
healthy individuals was needed in this segment of work. This in turn could be used to widen 
the understanding of bacterial variability in humans and establish whether these findings are 
common to respiratory diseases in general, or solely under-disease conditions. 
In depth examinations of the human microbiome in both healthy individuals and patients 
affected by COPD or lung cancer may reveal new biomarkers (Spratlin, Serkova, Eckhardt, 




development. In this context, Huang et al. (2010) used a 16S rRNA PhyloChip on a group of 
eight patients suffering of COPD, with the aim of identifying significant pathogenic bacteria. 
They found 75 bacterial taxa that were detected in all COPD study participants, even in the 
patients who were undergoing antibiotic treatment. These results suggest that detection of 
pathogenic bacteria can potentially be used in identifying therapeutic targets to improve 
exacerbation treatment for individuals suffering of COPD and potentially be applied to patients 
suffering of lung cancer or other respiratory diseases.  
 
4.5 | Conclusions and Future Work 
The findings suggest that from a small sample size, through microbiomic sequencing analyses, 
the taxonomic composition of bacterial population can be defined. Based on this, lung function 
with respect to specific respiratory diseases can be suggested. The conventional notion which 
states that lungs are a sterile environment has long been contradicted (Charlson et al., 2011). 
Notably, the lung microbiota has been analysed in numerous studies in patients suffering from 
Cystic Fibrosis and asthmatic patients. However, new investigations that focus on other 
respiratory diseases with wider impact such as COPD and lung cancer are required. These 
studies are needed in order to establish whether the patients’ lung microbiome suffers 
alterations specifically caused by the disease symptoms or they are just a manifestation of the 








CHAPTER 5 | General Discussion and Conclusions 
 
In this research project, it has been proven that changes in certain metabolites and bacteria can 
allow the differentiation between COPD, LC and healthy patients.  
The research assignment addressed this by employing metabolomics fingerprinting on a sample 
cohort. This allowed the identification of a range of metabolites that were proficient enough to 
differentiate between certain respiratory diseases and healthy controls (never, current, ex-
smokers). Although the identity of individual metabolites was not established, potential 
biomarkers were suggested, that allowed discrimination between the four groups created 
COPD, LC, HC and Other.  
The metabolomics fingerprinting technique based on saliva samples, has the potential of 
generating a high-throughput, cost-effective, non-invasive method of screening and diagnosing 
patients suffering of specific diseases, not only of the pulmonary nature. A larger cohort would 
undeniably be needed in order to confirm the accuracy of the results presented in this study and 
ascertain they are not artefacts. However, the technique of flow infusion electrospray mass 
spectrometry in saliva metabolomics fingerprinting suggests a promising outlook with regards 
to disease types and stages. 
The second approach of this research project was to employ 16S rRNA amplicon sequencing 
in order to establish the distinct bacterial taxonomic composition of COPD, COPD 
Exacerbation, HC and LC classes. Patients which were undergoing an exacerbation had 
significantly lower bacterial loads when compared to the other categories. This in turn may 
offer insights of the clinical features of respiratory diseases in relation to the levels of bacterial 





As with the lung metabolome investigation, the lung microbiome would require a larger cohort 
as well, in order to accurately discriminate between COPD, lung cancer, healthy controls and 
other respiratory diseases down to a genus and possibly species level. Additionally, a complete 
set of variables such as FEV1%, co-morbidities, stable or exacerbated condition, would be 
required for all patients for the completeness of results. 
 
The metabolomics and microbiomic approaches presented in here, both show differentiation 
between the COPD, lung cancer, other respiratory disease and healthy controls. With regards 
to the metabolome and microbiome work, insufficient samples were available in order to 
conduct both profiling techniques. Therefore, the metabolomics and microbiomic link of every 
sample was not possible. However, even if these results have been conducted at a small scale, 
saliva offered an unexpected reliability in the differentiation process for COPD, lung cancer 
and healthy controls. In both metabolomics (PCA analysis between classes, group heatmap) as 
well as microbiomic analyses (PCoA, PCA genera abundance of COPD stages, group 
heatmap), COPD and COPD Exacerbation groups showed an evident differentiation compared 
to LC, HC, Other classes. In the metabolomics Random Forest Plot, the COPD group displayed 
upregulated metabolites suggesting inflammation and in the microbiomics a-biodiversity 
measurement the COPD exacerbator group displayed a significant reduction suggesting 
potential immunological responses linked to reduced lung function.  
Metabolomic differentiation between the four classes was more evident in comparison with the 
microbiomic one. Specifically between LC and HC groups, but it must be mentioned that with 
the metabolomic analysis the PLS-DA was performed, which is a supervised analysis aiming 





Finally, one important future aim will be to understand the human microbiome through its 
metabolic products. The production of particular metabolites by bacteria in the human 
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PARTICIPANT INFORMATION SHEET – Version 3  20th February 2017 
 
Title of research programme: “Novel technologies for diagnosing and monitoring 
pulmonary diseases” 
 
REC reference: 16/WA/0036  IRAS reference:  187325 
 
You are being invited to take part in a research study.  Before you make a decision it is 
important to explain why the research is conducted and what it will involve.  Please take time 
to read the following information carefully and discuss it with friends, relatives and your GP if 
you wish. Do not hesitate to ask us if there is anything that is not clear or if you would like 
additional information.  Take time to decide whether or not you wish to take part in our study. 
 
 
1. What is the purpose of the research study? 
We believe that many lung diseases can change certain chemicals in people’s blood, saliva, 
urine and chest fluids. These chemicals or ‘biomarkers’ may be detectable even before a 
patient develops symptoms or we see changes on hospital scans and chest X-rays. We want 
to look at new tests including genetic testing in our research laboratories to try and work 
out which of these chemicals are different in people with lung disease and if these chemicals 
change with treatment. This research programme is contributing to an educational study, it 
may help to diagnose lung diseases earlier, and improve our care in the near future. 
 
2. Why have I been chosen to participate? 
Your doctor is concerned that you might be suffering from a lung condition. We would like 
your help by providing occasional extra samples when you attend our hospital for routine 
tests and treatment. 
 
3. Do I have to participate in this study? 
It is up to you to decide whether you would like to take part or not. If you decide to take 
part, you will be given this Participant Information Sheet and we will ask you to sign a 
Consent form. You are free to withdraw from the study at any time without providing us 
with a reason. 
 
4. What will happen to me if I agree to participate in the research? 
Firstly we will ask you some questions about your health. We will then ask you to breathe 
deeply into a tube measuring the amount of carbon monoxide in your breath and spit into 
a collection container. We may then ask you to provide us with a blood and urine sample.  
We may ask to take an extra biopsy or sample of fluid from the lung only if you are 
undergoing this procedure as part of your routine care. We will take the samples at the same 
time of this procedure.  
It is up to you to decide what sample(s) you want to provide us with, depending on how 











After the first set of samples, you may be contacted again by letter to ask if you are willing 
attend a follow up review where the researcher will again ask you questions about your 
health, a blowing test will be performed and the sputum, blood and urine samples will be 
collected. This will be timed to coincide with routine appointments wherever possible but 
may occur at another time more convenient to you. 
The samples will be stored in the Hywel Dda University Health Board and sent to different 
research institutions who are collaborating with the doctors there. These include research 
laboratories in Aberystwyth University and/or other institutions for specialized laboratory 
analyses that are not currently available in hospitals. The samples you provide now, will be 
kept and may also be used for new tests in the future if new technologies are invented. 
At present we dispose of all samples after 10 years. However, we are looking at transferring 
them to a long term local storage tissue bank. We are currently applying for government 
approval for this longer term storage and if this is granted, your samples will be moved to 
this facility in the Health Board. 
If you want, you can request for your samples to be disposed of at any time. 
 
5. What will I have to do? 
There are no lifestyle restrictions if you help. We will want you to continue your normal 
activities and all usual health treatments and medications will be unchanged.  
If you attend hospital at a later date, we may ask you again for samples to see if the 
‘biomarkers’ have changed e.g. after treatment for your lung condition. Again, we would 
only ask you for biopsy or a lung fluid sample if you were having samples taken as part of 
your routine hospital treatments. 
 
6. What are the side effects of participating in this study? 
There are no known side effects from taking part in this study, but we will need 5 minutes 
of your time to answer the screening questions and consequently up to 60 minutes do the 
breath, sputum and blood tests depending on the number of samples you want to provide 
us with. The extra biopsy or sample of lung fluid will take around 30 extra seconds and 
will only occur after your routine samples have been taken and if the doctor doing the 
routine procedure is satisfied that taking an additional sample at the same time is 
acceptable. 
 
7. What are the benefits associated with me taking part in this research study? 
The results of the research will have no direct benefits to you but may benefit patients with 
lung diseases in the future by moving towards earlier diagnosis and more personalized 
treatments. Unfortunately, we cannot pay you for participating in this study. 
 
8. What will happen if something goes wrong? 
If you feel that you have any reason to complain about any aspect of the way you have been 
approached in the hospital or further treated during the course of the study, the normal 






Supplementary Figure 3.1 | Participant Information Sheet utilised for patient 
recruitment at Bronglais, Glangwili and Prince Philip General Hospitals.  
Patients attending weekly respiratory clinics were screened by lung consultants. The 
Participant Information Sheet was then posted to potential eligible patients prior to their 
visits to the hospital.  This process was done in order to allow patients enough time to reflect 






9. Will my participation in this study be kept confidential? 
All the collected information about you during the course of our research programme will 
be kept strictly confidential. Any information that leaves the hospital will be coded so you 
cannot be identified from it. In addition, we will not give any identifiable information to 
life insurance, private medical insurance companies or any other third parties.  
 
10. What will happen with the results generated by this research programme? 
The findings from our study may be published in scientific journals and presented at 
conferences in a fully anonymized way. You are welcome to contact the researchers for a 
report every 2-3 years.   
 
11. Who is organizing and funding this research? 
This research is the result of a collaboration between Hywel Dda University Health Board 
and Aberystwyth University. It is funded by the European Social Fund, the Brazilian 
Government through the project “Science without Borders,” Tenovus Charity and a 
pharmaceutical company ProTEM Services Ltd. The company has had no influence on the 
design of this research and will not keep samples but it jointly funds a KESS PhD student 
within the University. 
 
12. Who has reviewed the study? 
Our research study has undergone review by medical doctors and scientific researchers 
within Hywel Dda University Health Board and across Wales As well as an NHS Research 
Ethics Committee (WALES REC 7).  
 
Contacts for further information: 
For independent advice, please contact Mr Chris Tattersall, R&D Department, Withybush 
Hospital, Tel: 01437 773813. 
Email: chris.tattersall@wales.nhs.uk 
 
If you have any further queries please do not hesitate to contact: 
 
Prof. Keir Lewis 
Chief Investigator 
Hon. Consultant, Hywel Dda University Health Board & 
Professor of Respiratory Medicine, Swansea University 













Supplementary Table 3.1 | COPD Group 
 Patients affected by COPD classified by gender and age group in accordance with the 







Supplementary Table 3.2 | Other Diagnoses Group 
Patients suffering of various respiratory diseases including idiopathic pulmonary fibrosis, 
bronchiectasis, asthma, pneumonia and sarcoidosis were analysed as a whole group named 











Supplementary Table 3.3 | Lung Cancer Group 
Patients with confirmed lung cancer diagnoses classified by gender and age group according 
to their smoking status and smoking pack years mean. 
 
Supplementary Table 3.4 | Healthy Control Group  
Table composed of healthy individuals that were currently smoking or former smokers at the 
time of the recruitment. The table has been constructed based on the individuals’ gender, age 










Supplementary Table 3.5 | Summarised Frequent Respiratory Comorbidities, Drug and 
Medical Histories Found in Recruited Patients from the COPD, LC and Other Groups 
Summarised patient information detailing frequent clinical data such as comorbidities, drug 




Supplementary Table 3.6 | Summarised Frequent Cardiac Comorbidities, Drug History, 
Use and Medical History in Recruited Patients from the COPD, LC and Other Groups 
Summarised clinical data information from patients suffering of COPD, LC or other 
respiratory diseases with the most frequent cardiac comorbidities. Attached there is also the 







Supplementary Table 4.1 | Nextera XT Index Primer1 (N7) and Nextera XT Index 
Primer2 (S5) from Illumina 
Nextera index primers used in the 16S rRNA Amplicon Sequencing analysis for the sequence 
construction (Table adapted after Cameron, 2015). 
Sample ID 
Nextera XT Barcode 
Index 1 (i7) Sequence Index 2 (i5) Sequence 
A001 COPD  N701 TAAGGCGA S517 GCGTAAGA 
A004 HC  N702 CGTACTAG S517 GCGTAAGA 
A030 COPD N703 AGGCAGAA S517 GCGTAAGA 
A035 COPD N704 TCCTGAGC S517 GCGTAAGA 
A038 Other N705 GGACTCCT S517 GCGTAAGA 
A039 LC N706 TAGGCATG S517 GCGTAAGA 
A041 Other N707 CTCTCTAC S517 GCGTAAGA 
A042 COPD N708 CAGAGAGG S517 GCGTAAGA 
A046 HC N709 GCTACGCT S517 GCGTAAGA 
A048 HC N710 CGAGGCTG S517 GCGTAAGA 
A052 HC N711 AAGAGGCA S517 GCGTAAGA 
A054 COPD N712 GTAGAGGA S517 GCGTAAGA 
A055 COPD N701 TAAGGCGA S502 CTCTCTAT 
A058 COPD N702 CGTACTAG S502 CTCTCTAT 
A059 HC N703 AGGCAGAA S502 CTCTCTAT 
A061 COPD N704 TCCTGAGC S502 CTCTCTAT 
A062 COPD N705 GGACTCCT S502 CTCTCTAT 
A063 COPD N706 TAGGCATG S502 CTCTCTAT 
A067 COPD N707 CTCTCTAC S502 CTCTCTAT 
A071 COPD N708 CAGAGAGG S502 CTCTCTAT 
A075 COPD N709 GCTACGCT S502 CTCTCTAT 
A077 COPD N710 CGAGGCTG S502 CTCTCTAT 
Supplementary Table 3.7 | Summarised General Comorbidities in Recruited Patients 
Suffering of Respiratory Diseases 
Summarised clinical data information of comorbidities, from patients recruited for the COPD, 




A078 HC N711 AAGAGGCA S502 CTCTCTAT 
A079 HC N712 GTAGAGGA S502 CTCTCTAT 
A086 HC N701 TAAGGCGA S503 TATCCTCT 
A087 HC N702 CGTACTAG S503 TATCCTCT 
A088 HC N703 AGGCAGAA S503 TATCCTCT 
A089 COPD N704 TCCTGAGC S503 TATCCTCT 
A090 LC N705 GGACTCCT S503 TATCCTCT 
A091 HC N706 TAGGCATG S503 TATCCTCT 
A093 HC N707 CTCTCTAC S503 TATCCTCT 
A094 LC N708 CAGAGAGG S503 TATCCTCT 
A095 HC N709 GCTACGCT S503 TATCCTCT 
A101 COPD N710 CGAGGCTG S503 TATCCTCT 
A105 COPD N711 AAGAGGCA S503 TATCCTCT 
A109 COPD N701 GTAGAGGA S504 AGAGTAGA 
A110 COPD N702 TAAGGCGA S504 AGAGTAGA 
A112 COPD N703 CGTACTAG S504 AGAGTAGA 
A114 HC N704 AGGCAGAA S504 AGAGTAGA 
A115 COPD N705 TCCTGAGC S504 AGAGTAGA 
A116 COPD N706 GGACTCCT S504 AGAGTAGA 
A117 HC N707 TAGGCATG S504 AGAGTAGA 
A118 COPD N708 CTCTCTAC S504 AGAGTAGA 
A120 HC N709 CAGAGAGG S504 AGAGTAGA 
A121 Other N710 GCTACGCT S504 AGAGTAGA 
A122 HC N711 CGAGGCTG S504 AGAGTAGA 
A123 HC N712 AAGAGGCA S504 AGAGTAGA 
A124 HC N701 GTAGAGGA S505 GTAAGGAG 
A125 HC N702 TAAGGCGA S505 GTAAGGAG 
A126 COPD N703 CGTACTAG S505 GTAAGGAG 
A127 HC N704 AGGCAGAA S505 GTAAGGAG 
A129 COPD N705 TCCTGAGC S505 GTAAGGAG 
A131 COPD N706 GGACTCCT S505 GTAAGGAG 
A133 COPD N707 TAGGCATG S505 GTAAGGAG 
A134 LC N708 CTCTCTAC S505 GTAAGGAG 
A137 COPD N709 CAGAGAGG S505 GTAAGGAG 
A138 HC N710 GCTACGCT S505 GTAAGGAG 
A141 HC N711 CGAGGCTG S505 GTAAGGAG 
A145 COPD N712 AAGAGGCA S505 GTAAGGAG 
A147 COPD N701 GTAGAGGA S506 ACTGCATA 
A149 HC N702 TAAGGCGA S506 ACTGCATA 
A161 COPD N703 CGTACTAG S506 ACTGCATA 
B002 COPD N704 AGGCAGAA S506 ACTGCATA 
B005 COPD N705 TCCTGAGC S506 ACTGCATA 
B011 Other N706 GGACTCCT S506 ACTGCATA 
B012 COPD N707 TAGGCATG S506 ACTGCATA 
B014 COPD N708 CTCTCTAC S506 ACTGCATA 
B015 HC N709 CAGAGAGG S506 ACTGCATA 




C009 COPD N711 CGAGGCTG S506 ACTGCATA 
C010 COPD N701 TAAGGCGA S517 GCGTAAGA 
C011/C004 COPD N702 CGTACTAG S517 GCGTAAGA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
